Venlosstat used in a method for reducing levels of disease-related biomarkers in patients with ganglioside storage disorders
By administering venlustat to patients with ganglioside storage disorders, the levels of biomarkers in plasma and cerebrospinal fluid were reduced, overcoming the limited effectiveness of existing treatments in neural tissue and achieving significant biomarker reductions.
Patent Information
- Application Number
- CN202480091060.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-04-19
- Filing Date
- 2025-04-17
- Publication Date
- 2026-11-17
AI Technical Summary
Currently, there is a lack of effective treatments to reduce the levels of biomarkers for GM2 ganglioside storage disease and other ganglioside storage disorders, and existing treatment strategies have limited effectiveness in neural tissue.
Administration of venollustat or its pharmaceutically acceptable salts to patients with ganglioside storage disorders reduces the accumulation of glycosphingolipids by lowering the levels of specific biomarkers such as GM1, GM2, GM3, and GL1 in plasma and cerebrospinal fluid.
It significantly reduced patients' biomarker levels, such as GM2, GM3, and GL1, demonstrating potential therapeutic effects on neural tissue.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
[0001] This article provides a method in which venglustat is administered to a patient suffering from ganglioside storage disorders such as GM2 ganglioside storage disorders like Sandhoff disease or Tay-Sachs disease, GM1 ganglioside storage disorders, or sialic acid storage disorders. The method is designed to reduce the levels of disease-related biomarkers in the patient. Pharmaceutical formulations for use in the method of the invention are also provided. Background Technology
[0002] GM2 ganglioside storage disorders are extremely rare, progressive autosomal recessive lysosomal storage disorders for which there is currently no approved treatment. These disorders occur due to a pathogenic variant in the HEXA and / or HEXB genes resulting in a deficiency of the enzyme β-aminohexosidase A (Tai-Sachs disease) or a combined deficiency of β-aminohexosidase A and B (Sanderhoff disease). The associated disorders occur in patients with a deficiency of the GM2 activator protein encoded by the GMA2 gene (the so-called GM2 AB variant). In each case, affected individuals have impaired lysosomal degradation of GM2 gangliosides and other glycolipids, leading to their accumulation in the lysosomes of cells and elsewhere in the body. This accumulation causes cytotoxic effects (particularly in neurons), resulting in progressive neurological damage, including motor deficits, progressive weakness, hypotonia, decreased responsiveness, visual impairment, and seizures. Several potential approaches for treating GM2 ganglioside storage disorders have been investigated, including enzyme replacement therapy (“ERT”, in which a functional form of the defective enzyme is injected into the patient), substrate reduction therapy (“SRT”, in which agents (typically small molecule drugs) are administered to modulate the glycosphingolipid pathway to reduce the accumulation of stored lipids), pharmacological companion therapy (in which agents are administered to assist in proper protein folding and transport to lysosomes), gene therapy (in which a functional form of the defective gene is introduced into the patient), and stem cell therapy (in which hematopoietic stem cells are transplanted into the patient). Early studies (including ERT) have shown that increasing or restoring β-aminohexosidase activity in human patients can affect stored lipids in visceral tissues, but the effect on neural tissues is limited (see, for example, Johnson et al., BirthDefects Orig. Artic. Ser. [Birth Defects Original Paper Series] (1973) 9:120-124). For example, direct administration of therapeutic agents to the brain using gene therapy vectors carrying functional copies of the HEXA or HEXB genes has shown promising results in animal models (see, for example, Gray-Edwards et al., Hum. Gene Ther. [Human Gene Therapy] (2018) 29:312-326), but has not yet been adequately evaluated in humans (see, for example, Flotte et al., Nat Med. [Nature Medicine] (2022) 28(2):251-259 for preliminary results from a trial in two human subjects). Studies on the effects of SRT in treating GM2 ganglioside storage disease have shown some promise in animal models, but these have not yet translated into any authorized therapies for human use.For example, iminosaccharide-based inhibitors of the enzyme glucosamine synthase (“GCS”), such as milustat, have been studied in mouse models of GM2 ganglioside storage disease (see, for example, Platt et al., Phil. Trans. R. Soc. Lond. B [Philosophical Transactions of the Royal Society B Series] (2003) 358:947-954) and in patients with late-onset Tay-Sachs disease (see, for example, Shapiro et al., Genet Med. [Medical Genetics] (2009) 11(6):425-433), although this has not led to any authorized treatment. Milustat (also known as NB-DNJ) is authorized for the treatment of Gaucher disease and Pompe disease (two other lysosomal storage diseases that lead to the accumulation of toxic substrates).
[0003] Other extremely rare conditions exist, in which a deficiency of ganglioside processing enzymes leads to the accumulation of stored lipids. GM1 ganglioside storage disease is a progressive neurosomatic disorder caused by mutations in β-galactosidase encoded by the GLB1 gene. β-galactosidase cleaves β-linked galactose residues from the non-reducing ends of the glycan moieties found in various glycoconjugates, such as GM1. Decreased β-galactosidase activity leads to the accumulation of GM1 gangliosides and its desialyl derivative GA1, primarily in lysosomes of neuronal tissue. Clinical symptoms include hepatosplenomegaly, cardiomyopathy, skeletal disorders, and epilepsy (especially in the early-onset form of the disease), as well as cerebellar dysfunction and progressive dementia in a late-onset form. Several therapeutic strategies for treating GM1 ganglioside storage disease have been proposed, including several similar to those discussed above regarding GM2 ganglioside storage disease. Therefore, ERT, SRT, drug companion therapy, gene therapy, and stem cell transplantation have all been proposed. Although animal models have been studied, there are no authorized treatments for the condition—several clinical trials of gene therapy are underway (see, for example, Rha et al., App. Clin. Genet. [Applied Clinical Genetics] (2021) 14:209-233). Sialic acid storage disease is caused by a deficiency of the enzyme neuraminidase-1 (typically due to mutations in the NEU1 gene), which leads to the progressive accumulation of oligosaccharides and sialylated glycoproteins in cells. Symptoms of sialic acid storage disease can include growth problems, visual impairment, myoclonus, ataxia, and seizures. There are no authorized treatments for sialic acid storage disease.
[0004] Venlulstat (also known as (S)-quininecyclo-3-yl-2-(2-(4-fluorophenyl)thiazolyl-4-yl)propyl-2-ylcarbamate) is a small molecule drug that has been proposed for the treatment of conditions including lysosomal storage diseases such as Gaucher disease and Fabry disease (see, for example, International Patent Application No. PCT / US2012 / 029417, published as WO 2012 / 129084, the contents of which are hereby incorporated by reference in their entirety). Venlulstat, as an inhibitor of the enzyme glucosinolate synthase (GCS), has been shown to work in these treatments by reducing the level of glycosphingolipid GL1. Early clinical studies have shown that venlulstat exhibits an acceptable safety profile when administered to healthy individuals at doses up to about 15 mg / day (see, for example, Peterschmitt et al., Clin Pharmacol Drug Dev [Clinical Pharmacology in Drug Development] (2021) 10(1):86-98). The effects of venulose on patients with ganglioside storage disorders have not been reported.
[0005] In the absence of any authorized treatment options, there is an urgent need for agents that can affect the pathophysiology and / or clinical course of GM2 ganglioside storage disorder and other ganglioside storage disorders. Summary of the Invention
[0006] This disclosure describes the results of clinical studies monitoring the effects of venulostatine on biomarkers of ganglioside storage diseases in human patients. These results enable the development of methods designed to reduce the levels of specific biomarkers in the plasma and / or cerebrospinal fluid (CSF) of such patients. These biomarkers include sphingolipid-containing compounds such as GM1, GM2, and GM3, which are presumed to have cytotoxic effects in vivo. Not wishing to be bound by theory, this application relates to methods in which venulostatine is administered to human patients to reduce the levels of these disease-related sphingolipid-containing compounds. These methods may also reduce the levels of proteins in the CSF associated with lysosomal storage diseases and / or neurodegeneration, as described below.
[0007] Therefore, in a first aspect, this disclosure provides a method for reducing the level of a biomarker in the biological fluid of a subject in need of having a ganglioside storage disorder, the method comprising administering to the subject an effective amount of venulostat or a pharmaceutically acceptable salt thereof, wherein the biomarker is selected from the group consisting of GM1, GM2, GM3, GL1 and combinations thereof.
[0008] On the other hand, this disclosure provides a method for administering venulstat or a pharmaceutically acceptable salt thereof to a subject in need who has a ganglioside storage disorder, wherein the venulstat or a pharmaceutically acceptable salt thereof is administered in an effective amount to reduce the level of biomarkers in the subject's biological fluid.
[0009] In the embodiments, the biofluid is selected from the group consisting of plasma and CSF.
[0010] In the embodiments, the biomarker is selected from: (a) GM1, optionally in combination with GM3 and / or GL1; (b) GM2, optionally in combination with GM3 and / or GL1; and (c) GM3, optionally in combination with GM2 and / or GL1.
[0011] In the embodiments, administration of venulosat or a pharmaceutically acceptable salt thereof reduces the level of the biomarker by at least about 30%, such as at least about 40%, 50%, 60%, 70%, or 80%.
[0012] In the embodiments, the venulilstat or its pharmaceutically acceptable salt is administered orally, for example, in the form of tablets or capsules.
[0013] In the example, venulostatine or a pharmaceutically acceptable salt thereof was administered once daily.
[0014] In the examples, the subject was 18 years of age or older and was administered venlulstat or a pharmaceutically acceptable salt thereof at a dose of approximately 15 mg / day (calculated as free base); or the subject was less than 18 years of age and was administered venlulstat or a pharmaceutically acceptable salt thereof at the following doses (calculated as free base):
[0015] (a) For subjects weighing ≥ 50 kg, approximately 15 mg / day;
[0016] (b) For subjects weighing 30 kg to < 50 kg, approximately 12 mg / day;
[0017] (c) For subjects weighing 15 kg to < 30 kg, approximately 6 mg / day; or
[0018] (d) For subjects weighing 10 kg to < 15 kg, approximately 4 mg / day.
[0019] In the embodiments, the venlolactone is in the form of venlolactone free base or a pharmaceutically acceptable salt of venlolactone, optionally in the form of venlolactone L-malate.
[0020] In the embodiments, the ganglioside storage disorder is selected from GM2 ganglioside storage disorder (e.g., Sandhoff's disease or Tai-Sachs disease) and GM1 ganglioside storage disorder.
[0021] On the other hand, this disclosure provides a method for reducing the level of a biomarker in the biological fluid of a subject in need of GM2 ganglioside storage disorder, the method comprising administering to the subject an effective amount of venulilstat or a pharmaceutically acceptable salt thereof, wherein the biomarker is GM2, optionally in combination with GM3 and / or GL1.
[0022] In the examples: (a) the GM2 ganglioside storage disease is Ty-Sachs disease, and the administration of venulosamine or a pharmaceutically acceptable salt thereof reduces the GM2 level in the CSF by at least about 30%; or (b) the GM2 ganglioside storage disease is Sandhoff disease, and the administration of venulosamine or a pharmaceutically acceptable salt thereof reduces the GM2 level in the CSF by at least about 40%.
[0023] In the embodiment, the GM2 ganglioside storage disease is juvenile GM2 ganglioside storage disease, and the administration of venollustat or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) the GM2 level in the CSF by at least about 30%.
[0024] In the examples, administration of venulister or a pharmaceutically acceptable salt thereof reduced plasma GM2 levels to between approximately 200 ng / mL and approximately 750 ng / mL.
[0025] On the other hand, this disclosure provides a method for reducing the level of a biomarker in the biological fluid of a subject in need of GM1 ganglioside storage disorder, the method comprising administering to the subject an effective amount of venulilstat or a pharmaceutically acceptable salt thereof, wherein the biomarker is GM1, optionally in combination with GM3 and / or GL1.
[0026] In the embodiments, administration of venulister or a pharmaceutically acceptable salt thereof reduces the GM1 level in the CSF to a level between approximately 25 ng / mL and 65 ng / mL, and / or reduces the GM1 level in the plasma to a level between approximately 40 ng / mL and approximately 115 ng / mL.
[0027] In the embodiment, the subject suffers from ganglioside storage disorder GM2 ganglioside storage disease, and: (i) the method also reduces the CD63 level in the subject's CSF; (ii) administration of an effective amount of venlolactone or a pharmaceutically acceptable salt thereof also reduces the CD63 level in the subject's CSF; or (iii) administration of an effective amount of venlolactone or a pharmaceutically acceptable salt thereof also reduces the CD63 level in the subject's CSF.
[0028] In the examples: (a) the GM2 ganglioside storage disease is adult-onset Tay-Sachs disease or adult-onset Sandhoff disease, and the administration of venulilstat or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) the CD63 level in the CSF by at least about 30%; or (b) the GM2 ganglioside storage disease is juvenile GM2 ganglioside storage disease, and the administration of venulilstat or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) the CD63 level in the CSF by at least about 35%.
[0029] In the embodiment, the subject suffers from ganglioside storage disorder, which is juvenile GM2 ganglioside storage disorder, and: (i) the method also reduces the NFL level in the subject's CSF; (ii) administration of an effective amount of venlolactone or a pharmaceutically acceptable salt thereof also reduces the NFL level in the subject's CSF; or (iii) administration of the effective amount of venlolactone or a pharmaceutically acceptable salt thereof also reduces the NFL level in the subject's CSF.
[0030] In the embodiments, administration of venulosamine or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) the NFL level in the CSF by at least about 50%.
[0031] Another aspect of this disclosure provides venulilstat or a pharmaceutically acceptable salt thereof for use in the methods defined above.
[0032] Another aspect of this disclosure provides the use of venulilstat or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical agent for use in the methods defined above.
[0033] Further features and advantages of the methods disclosed herein will become clear from the following detailed embodiments. Attached Figure Description
[0034] Figure 1This diagram illustrates a portion of the glycosphingolipid pathway, highlighting the relationships between various ganglioside glycosphingolipids (GM1, GM2, GM3), the enzymes responsible for processing those glycosphingolipids, and the diseases resulting from mutations in the corresponding genes.
[0035] Figure 2 GM2 levels are shown in the primary population (patients with Ty-Sachs disease or Sandhof disease) receiving venulister or placebo. CSF GM2 levels at week 104 are also shown. Figure 2 A) and plasma GM2 levels at weeks 12–104 ( Figure 2 The result of B).
[0036] Figure 3 The GM2 levels in patients with Ty-Sachs disease and Sandhof disease who received venulister or placebo are shown. CSF GM2 levels at week 104 are also shown. Figure 3 A) and plasma GM2 levels at weeks 12–104 ( Figure 3 The result of B).
[0037] Figure 4 The GM3 levels in patients with Ty-Sachs disease and Sandhof disease who received venulister or placebo are shown. CSF GM3 levels at week 104 are also shown. Figure 4 A) and plasma GM3 levels at weeks 12–104 ( Figure 4 Results for B). “-” indicates that no biomarkers were measured.
[0038] Figure 5 The GL1 levels in patients with Ty-Sachs disease and Sandhof disease who received venulister or placebo are shown. CSF GL1 levels at week 104 are also shown. Figure 5 A) and plasma GL1 levels at weeks 12–104 ( Figure 5 The result of B).
[0039] Figure 6 The correlation between baseline aminohexosidase levels and changes in GM2 levels in CSF from baseline to 104 weeks is shown in the primary population receiving venulister (patients with Ty-Sachs disease and Sandhof disease). Spearman correlation coefficients are shown.
[0040] Figure 7 GM1 levels are shown in patients with GM1 ganglioside storage disease who received venulister GM1. CSF GM1 levels at week 104 are also shown. Figure 7 A) and plasma GM1 levels at weeks 12–104 ( Figure 7 Results for B). “-” indicates that no biomarkers were measured.
[0041] Figure 8 GM2 levels are shown in patients with GM2 ganglioside storage disease who received venulister GM2. CSF GM2 levels are shown at week 104. Figure 8 A) and plasma GM2 levels at weeks 12–104 ( Figure 8 Results for B). “-” indicates that no biomarkers were measured.
[0042] Figure 9 The GL1 levels in patients with GM1 and GM2 ganglioside storage disorders who received venulostatine are shown. CSF GL1 levels at week 104 are also shown. Figure 9 A) and plasma GL1 levels at weeks 12–104 ( Figure 9 The result of B).
[0043] Figure 10 The levels of CD63 at baseline in CSF samples from patients in the primary and secondary populations are shown. Box plots from left to right show: patients in the primary population receiving placebo (n = 15); patients in the primary population receiving veneluxat (n = 30); patients in the secondary population receiving veneluxat with juvenile GM2 ganglioside storage disease (n = 7); and patients in the secondary population receiving veneluxat with GM1 ganglioside storage disease (n = 4). The y-axis represents CD63 levels in relative units on a linear scale.
[0044] Figure 11 The percentage change in CD63 levels at week 104 (compared to baseline) in CSF samples from patients in the primary and secondary populations is shown. Box plots from left to right show: patients receiving placebo in the primary population (n = 15); patients receiving venelusstat in the primary population (n = 29); patients with juvenile GM2 ganglioside storage disease receiving venelusstat in the secondary population (n = 7); and patients with GM1 ganglioside storage disease receiving venelusstat in the secondary population (n = 4).
[0045] Figure 12 The levels of NFL at baseline in CSF samples from patients in the primary and secondary populations are shown. Box plots from left to right show: patients receiving placebo in the primary population (n = 15); patients receiving venollustat in the primary population (n = 30); patients with juvenile GM2 ganglioside storage disease receiving venollustat in the secondary population (n = 7); and patients with GM1 ganglioside storage disease receiving venollustat in the secondary population (n = 4).
[0046] Figure 13The percentage change in NFL levels at week 104 (compared to baseline) in CSF samples from patients in the primary and secondary populations is shown. Box plots from left to right show: patients receiving placebo in the primary population (n = 15); patients receiving venulostat in the primary population (n = 30); patients with juvenile GM2 ganglioside storage disease receiving venulostatat in the secondary population (n = 7); and patients with GM1 ganglioside storage disease receiving venulostatatat in the secondary population (n = 4). Detailed Implementation
[0047] Although specific embodiments of the present disclosure will now be described with reference to preparation and formulation, it should be understood that such embodiments are by way of example only and illustrate only a small number of the many possible specific embodiments that may represent the application of the principles of the present disclosure. In view of the benefits of the present disclosure, various changes and modifications will be apparent to those skilled in the art and are considered to be within the spirit and scope of the present disclosure as further defined in the appended claims.
[0048] definition
[0049] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. While any methods and materials similar to or equivalent to those described herein may be used in the practice or testing of this disclosure, exemplary methods, apparatus, and materials are described hereafter. All technical and patent disclosures referenced herein are incorporated herein by reference in their entirety.
[0050] Unless otherwise instructed, the practices disclosed herein will employ conventional techniques within the scope of the art, including tissue culture, immunology, molecular biology, microbiology, cell biology, and recombinant DNA. See, for example, Michael R. Green and Joseph Sambrook, Molecular Cloning (4th edition, Cold Spring Harbor Laboratory Press, 2012); Ausubel et al., eds. (2007) Current Protocols in Molecular Biology; MacPherson et al. (1991) PCR 1: A Practical Approach (IRL Press at Oxford University Press); and MacPherson et al. (1995) PCR 2: A Practical approach.
[0051] All numerical designations, such as pH, temperature, time, concentration, molecular weight, etc. (including ranges), are approximate values that vary (+) or (-) in increments of, for example, 0.1 or 1.0, where appropriate. It should be understood that, although not always explicitly stated, all numerical designations are preceded by the term "about" to indicate a typical level of variability. For example, a numerical designation for a given value "about" may vary by ±10% of said value; alternatively, the variation may be ±5%, ±2%, or ±1% of that value. It should also be understood that, although not always explicitly stated, the reagents described herein are merely exemplary, and their equivalents are known in the art.
[0052] Unless the context clearly indicates otherwise, the singular forms “a / an” and “the” as used in the specification and claims include plural indicators. For example, the term “biomarker” includes multiple biomarkers, including mixtures thereof. Unless explicitly stated or obvious from the context, the term “or” as used herein should be understood as inclusive. The term “comprising” as used herein means the phrase “including but not limited to” and is used interchangeably with it.
[0053] As used herein, the term "comprising" is intended to mean that a composition and method includes the listed elements, but does not exclude other elements. When used to define a composition and method, "consistently composed of" should mean excluding other elements that are of any significance to the stated purpose. Thus, a composition consisting essentially of elements as defined herein will not exclude trace contaminants from separation and purification methods, as well as pharmaceutically acceptable carriers such as phosphate-buffered saline, preservatives, etc. "Comprising" should mean excluding more than one trace element of other components and substantial method steps for administering the composition of this disclosure or process steps for producing the composition or achieving the intended results. Examples defined by each of these transitional terms are within the scope of this disclosure. The use of the term "comprising" herein is intended to cover both "consistently composed of" and "composed of".
[0054] The terms “subject,” “individual,” or “patient” are used interchangeably in this article and refer to a person.
[0055] As used herein, the term "healthy individual" typically refers to an individual who does not suffer from a condition suitable for treatment with venulilstat. Specifically, a healthy individual can be an individual who does not suffer from any of the following lysosomal storage diseases: GM2 ganglioside storage diseases (e.g., Sandhoff's disease or Tai-Sachs disease), GM1 ganglioside storage diseases, and sialic acid storage diseases. Healthy individuals typically do not have any GBA mutations and typically also lack pathogenic mutations in other genes encoding enzymes involved in the glycosphingolipid pathway (e.g., β-aminohexosidases (e.g., Hex A or Hex B), GM1-β-galactosidase, GM2 ganglioside activator protein, and neuraminidase).
[0056] "Administration" is defined herein as the means of delivering a pharmaceutical agent (e.g., an active ingredient) or a composition containing a pharmaceutical agent to a subject in a manner that results in the presence of the agent in the subject's body, or the means of prescribing, instructing, administering, or supervising another person (including the subject) to so deliver said pharmaceutical agent or composition. Such administration can be carried out via any route, including but not limited to oral, skin, transdermal, transmucosal (e.g., vaginal, rectal, buccal, or sublingual), injection (e.g., subcutaneous, intravenous, intraperitoneal, intrathecal, intramuscular, intradermal), and inhalation (e.g., lung, nasal). Of course, pharmaceutical formulations are given in a form suitable for each route of administration. Administration can also be local or systemic in nature. For example, while oral and injectable routes of administration generally provide systemic exposure, some routes of administration provide only local exposure, such as local skin application and intradermal injection. Intranasal inhalation can provide local or systemic exposure. The compositions and methods disclosed herein are typically intended for enteral (e.g., oral) administration.
[0057] As used herein, when referring to therapeutic use, “co-administration” means administering two or more active ingredients to a patient as part of a treatment regimen for a disease or disorder, regardless of whether the two or more active ingredients are administered at the same or different times or via the same or different routes of administration. Co-administration of the two or more active ingredients may be performed at different times of the same day, on different dates, or at different frequencies.
[0058] As used herein, when referring to therapeutic use, the term "simultaneously" means the administration of two or more active ingredients at the same time or approximately at the same time, and via the same route of administration. This can refer to the administration of the two or more active ingredients in a single dosage form or in multiple separate dosage forms, administered at the same time or approximately at the same time. For example, this can refer to the administration to a patient of a single oral tablet or capsule containing two or more active ingredients, or the administration of two or more oral tablets or capsules containing two or more active ingredients therein.
[0059] As used herein, when referring to therapeutic use, the term "separately" means administering two or more active ingredients at the same time or approximately the same time via different routes of administration, or administering two or more active ingredients at different times via the same or different routes of administration. For example, the term "separately" includes administering one active ingredient by injection while simultaneously administering separate active ingredients orally when both administrations are performed at approximately the same time. Furthermore, the term "separately" includes administering one active ingredient orally at a specific time of day (e.g., in the morning) and separate active ingredients orally at different times of day (e.g., one hour later, or three hours later, or in the afternoon or evening) or on another day. Therefore, separate administration will also cover dosing regimens under which, for example, one drug is taken on days 1, 3, 5, etc., and another drug is taken on days 2, 4, 6, etc.
[0060] The phrase "at the same time or approximately the same time" should be understood to generally mean that the interval between two events is less than 30 minutes (e.g., less than 20 minutes, or less than 15 minutes, or less than 10 minutes, or less than 5 minutes). Where the events themselves occur over a period of time, such as intravenous administration of a drug over a 60-minute timeframe, "at the same time or approximately the same time" will include any overlap between such timeframes or the start of a new such timeframe approximately 30 minutes after the end of the previous timeframe.
[0061] As used herein, the term “treating” typically refers to an intervention that has a therapeutic or preventative effect (e.g., as indicated by a certain degree of clinical response over a specific timescale (e.g., 104 weeks)). However, the term “treating” can also include interventions that do not have a measurable or quantifiable clinical response over a specific timescale (e.g., 104 weeks). In terms of the degree to which treatment has a measurable therapeutic or preventative effect on a disease, “treating” a disease includes: (1) suppressing the disease, i.e., preventing or reducing the development of the disease or its clinical symptoms; and / or (2) alleviating the disease, i.e., causing the disease or its clinical symptoms to subside. “Preventing” a disease includes preventing the development of clinical symptoms of the disease in patients who may be susceptible to the disease but have not yet experienced or exhibited symptoms of the disease. A disease that is “suitable for treatment with a specific active agent” or “treatable by a specific active agent” in at least some patients who have the disease or are susceptible to the disease is a disease that can be treated and / or prevented by the active agent.
[0062] The term “having” in its context with the term “treatment” refers to a patient or individual who has been diagnosed with a disease. The term “having” in relation to the term “prevention” refers to a patient or individual who is susceptible to the disease. A patient may also be described as “at risk of having” the disease due to a family history of the disease or due to the presence of a gene mutation associated with the disease. Patients at risk of the disease have not yet developed all or some of the characteristic pathologies of the disease.
[0063] An “effective amount” or “therapeutic effective amount” is an amount sufficient to achieve a beneficial or desired outcome. An effective amount can be administered, applied, or dosed, either once or multiple times. Such delivery depends on many variables, including, for example, the time period during which each individual dose is administered, the bioavailability of the therapeutic agent, and the route of administration. However, it should be understood that the specific dose level of the therapeutic agent disclosed herein for any particular subject depends on a variety of factors, including, for example, the activity of the specific compound used, the subject’s age, weight, general health condition, sex, and diet, the time of administration, the severity of the specific disorder being treated, and the form of administration. Typically, dose-response relationships from in vitro and / or in vivo testing can initially provide useful guidance in administering an appropriate dose to a patient. Generally, it will be desirable to administer an amount of compound that effectively achieves plasma, serum, or CSF levels equivalent to concentrations found to be effective in vitro. The determination of these parameters is well known to those skilled in the art. These considerations, as well as effective formulations and administration procedures, are well known in the art and are described in standard textbooks. Consistent with this definition, as used herein, the term “therapeutic effective amount” is an amount sufficient to treat (e.g., improve) one or more symptoms associated with the disease or disorder described herein, either ex vivo, in vitro, or in vivo.
[0064] As used herein, the term "pharmaceuticalally acceptable excipient" encompasses any standard pharmaceutical excipient, including carriers such as phosphate-buffered saline solutions, water and emulsions (such as oil / water or water / oil emulsions), and various types of wetting agents. Pharmaceutical compositions may also contain stabilizers and preservatives. For examples of carriers, stabilizers, and adjuvants, see Remington's Pharmaceutical Sciences (20th edition, Mack Publishing Co., 2000).
[0065] As used herein, the term “pharmaceuticalally acceptable salt” means a pharmaceutically acceptable acid addition salt or a pharmaceutically acceptable base addition salt of the compounds disclosed herein, which can be administered without producing any one or more substantial undesirable biological effects or without producing any one or more harmful interactions with any other component that may be contained in the pharmaceutical composition.
[0066] Addition salts can be readily prepared using conventional techniques, for example by treating a base compound with a defined amount of a selected inorganic or organic acid in an aqueous solvent medium or in a suitable organic solvent (e.g., methanol or ethanol). Positively charged compounds (e.g., containing quaternary ammonium) can also form salts with the anionic components of a variety of inorganic and / or organic acids. Acids that can be used to prepare pharmaceutically acceptable acid addition salts are those that can form non-toxic acid addition salts, such as salts containing, for example, pharmacologically acceptable anions, such as chlorides, bromides, iodides, nitrates, sulfates or bisulfates, phosphates or acidic phosphates, acetates, lactates, citrates or acidic citrates, tartrates or bitartrates, succinates, malates, maleates, fumarates, gluconates, glycoses, benzoates, methanesulfonates, and bis(hydroxynaphthyl)ate [i.e., 1,1'-methylene-bis(2-hydroxy-3-naphthylcarbamate)]. The bases that can be used to prepare pharmaceutically acceptable base addition salts are those capable of forming non-toxic base addition salts. These base addition salts are, for example, salts containing pharmacologically acceptable cations (such as alkali metal cations (e.g., potassium and sodium), alkaline earth metal cations (e.g., calcium and magnesium)), ammonium, or other water-soluble amine addition salts, such as N-methylglucosamine (glucosamine), lower alkanol ammonium, and other such organic amine bases. Venuelstat addition salts are typically acid addition salts. In the examples, the pharmaceutically acceptable salt of venuelstat is venuelstat malate, particularly venuelstat L-malate.
[0067] Unless otherwise expressly stated, the mass of venelulstat mentioned herein corresponds to the mass of venelulstat calculated as free base. For example, "15 mg dose of venelulstat" means 15 mg of venelulstat free base, or the amount of venelulstat salt or prodrug that provides an equivalent molar amount (e.g., 20 mg of venelulstat malate). Therefore, throughout the product information, references to "venelulstat" include pharmaceutically acceptable salts and prodrugs of venelulstat, such as those described herein.
[0068] The description of embodiments of variables or aspects in this document includes embodiments as any single embodiment or in combination with any other embodiment or part thereof.
[0069] Any composition or method provided herein may be combined with one or more of any other compositions and methods provided herein.
[0070] The following abbreviations are used in this article:
[0071]
[0072] Methods for reducing disease-related biomarker levels in patients with ganglioside storage disorders
[0073] Venlustat (free base) has a chemical structure according to formula (I) below, and it can be readily provided as a malate addition salt (e.g., prepared as described in the examples below). Venlustat is an oral GCS inhibitor under development for the treatment of conditions including Fabry disease and Gaucher disease.
[0074]
[0075] This disclosure and the following examples describe the results of a clinical study in which venelusstat was administered to subjects with GM2 ganglioside storage disorders (Sanderhoff's disease and Ty-Sachs' disease), GM1 ganglioside storage disorders, and sialic acid storage disorders. In the administration regimen, venelusstat significantly reduced plasma and CSF levels of biomarkers, including sphingolipids, which can be considered part of the underlying pathology of toxic and / or disease-related conditions. Furthermore, a correlation was observed between the activity of the deficient enzyme (aminohexosidase in the case of GM2 ganglioside storage disorders) and the degree of reduction in biomarker levels. The results of this study support (at least partially) the corrective effect of venelusstat on disease-related biomarker levels in plasma and / or CSF of patients with GM2 ganglioside storage disorders and other ganglioside storage disorders.
[0076] Therefore, in one aspect, this disclosure provides a method for reducing the level of a biomarker in the biological fluid of a subject in need of having a ganglioside storage disorder, the method comprising administering to the subject an effective amount of venulostat or a pharmaceutically acceptable salt thereof, wherein the biomarker is selected from the group consisting of GM1, GM2, GM3, GL1 and combinations thereof.
[0077] In this regard, this disclosure provides venelusstat or a pharmaceutically acceptable salt thereof for use in a method for reducing the levels of biomarkers in the biological fluid of a subject in need of having ganglioside storage disorders, wherein the biomarkers are selected from the group consisting of GM1, GM2, GM3, GL1, and combinations thereof. This disclosure also provides venelusstat or a pharmaceutically acceptable salt thereof for use in a method as defined herein (e.g., as claimed in the appended claims).
[0078] In another related aspect, this disclosure provides the use of venelusstat or a pharmaceutically acceptable salt thereof in the preparation of an agent for use in a method for reducing the levels of biomarkers in the biological fluid of a human subject with ganglioside storage disorder, wherein the biomarkers are selected from the group consisting of GM1, GM2, GM3, GL1, and combinations thereof. This disclosure also provides the use of venelusstat or a pharmaceutically acceptable salt thereof in the preparation of an agent for use in a method as defined herein (e.g., as claimed in the appended claims).
[0079] Another aspect of this disclosure provides a method for administering venollustat or a pharmaceutically acceptable salt thereof to a subject in need who has a ganglioside storage disorder, wherein the venollustat or a pharmaceutically acceptable salt thereof is administered in an effective amount to reduce the level of biomarkers in the subject's biological fluid.
[0080] On the other hand, this disclosure provides a method for treating a human subject with ganglioside storage disorder, the method comprising administering to the subject an effective amount of venollustat or a pharmaceutically acceptable salt thereof, wherein the administration reduces the level of a biomarker in the subject's biological fluid, wherein the biomarker is selected from the group consisting of GM1, GM2, GM3, GL1, and combinations thereof. This disclosure further provides venollustat or a pharmaceutically acceptable salt thereof for use in the method of treating a human subject. This disclosure further provides the use of venollustat or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical preparation for use in the method of treating a human subject.
[0081] In embodiments, the biological fluid is selected from the group consisting of blood, blood fractions, and CSF. In embodiments, the biological fluid contains (e.g., is) whole blood or a blood fraction selected from plasma and serum. In embodiments, the biological fluid contains (e.g., is) whole blood. In other embodiments, the biological fluid contains (e.g., is) plasma or serum. In embodiments, the biological fluid contains (e.g., is) plasma. In embodiments, the biological fluid contains (e.g., is) CSF. In embodiments, the biological fluid is selected from the group consisting of plasma and CSF.
[0082] In one embodiment, the biomarker is GM1. In one embodiment, the biomarker is GM2. In one embodiment, the biomarker is GM3. In one embodiment, the biomarker is GL1. In one embodiment, the biomarkers are GM2 and GM3. In one embodiment, the biomarkers are GM2 and GL1. In one embodiment, the biomarkers are GM2, GM3, and GL1. In one embodiment, the biomarkers are GM1 and GM3. In one embodiment, the biomarkers are GM1 and GL1. In one embodiment, the biomarkers are GM1, GM3, and GL1. In one embodiment, the biomarkers do not include both GM1 and GM2. In one embodiment, the biomarkers are selected from: (a) the group consisting of GM1, GM3, GL1, and combinations thereof; and (b) the group consisting of GM2, GM3, GL1, and combinations thereof. In the embodiments, the biomarkers are selected from: (a) GM1, optionally in combination with GM3 and / or GL1; (b) GM2, optionally in combination with GM3 and / or GL1; and (c) GM3, optionally in combination with GM2 and / or GL1.
[0083] In one embodiment, the biofluid is plasma, and the biomarker is selected from: (a) GM1, optionally in combination with GM3 and / or GL1; (b) GM2, optionally in combination with GM3 and / or GL1; and (c) GM3, optionally in combination with GM2 and / or GL1. In other embodiments, the biofluid is CSF, and the biomarker is selected from: (a) GM1, optionally in combination with GM3 and / or GL1; (b) GM2, optionally in combination with GM3 and / or GL1; and (c) GM3, optionally in combination with GM2 and / or GL1.
[0084] In embodiments, administration of venulister or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) the level of the biomarker by at least about 10%, for example, at least about 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%. In embodiments, the level of the biomarker is reduced by at least about 30%, for example, at least about 40%, 50%, 60%, 70%, or 80%. The reduction in biomarker level is typically calculated relative to a baseline level, for example, relative to a level measured before the start of treatment (e.g., shortly before the start of treatment, such as, less than about 1 week before the start of treatment). Therefore, the reduction can typically be as high as but not exceed 100%. It should be understood that methods for quantifying biomarker levels (e.g., as described herein) typically have a lower limit of quantification and therefore may not be possible in practice to demonstrate a 100% reduction.
[0085] In embodiments, the aforementioned decrease in biomarker levels occurs within a period of approximately one week from the start of venelulstat administration. In embodiments, the decrease in biomarker levels occurs within the following time periods: approximately 4 weeks, approximately 8 weeks, approximately 12 weeks, approximately 16 weeks, approximately 24 weeks, approximately 30 weeks, approximately 40 weeks, approximately 52 weeks, or approximately 104 weeks. In embodiments, the aforementioned decrease in plasma biomarker levels occurs within a period of approximately 12 weeks from the start of venelulstat administration, or occurs within a period of at least approximately 12, 16, 24, 30, 40, 52, or 104 weeks. In embodiments, the aforementioned decrease in CSF biomarker levels occurs within a period of approximately 12 weeks from the start of venelulstat administration, or occurs within a period of at least approximately 12, 16, 24, 30, 40, 52, or 104 weeks. Previous studies on glycosphingolipid biomarkers have shown that the response of CSF biomarkers to treatment follows a similar curve to that of plasma biomarkers to treatment (see, for example, Schiffmann et al., Brain (2023) 146(2):461-474).
[0086] In one embodiment, venlulstat or a pharmaceutically acceptable salt thereof is administered orally, for example, in the form of tablets or capsules. In another embodiment, venlulstat or a pharmaceutically acceptable salt thereof is administered once daily (e.g., at approximately the same time each day).
[0087] In examples, venelusstat or a pharmaceutically acceptable salt thereof is administered at a dose from about 7 mg / day to about 20 mg / day (calculated as free base), for example, at a dose from about 12 mg / day to about 16 mg / day (e.g., about 15 mg / day) (calculated as free base). In examples, the aforementioned dose (e.g., about 15 mg / day) is administered to adult patients (patients aged 18 years or older and whose weight may be ≥ 50 kg). In examples, patients are juvenile or adolescent patients (patients under 18 years of age and whose weight may be ≤ 50 kg), and venelusstat or a pharmaceutically acceptable salt thereof is administered at a dose from about 4 mg / day to about 15 mg / day (calculated as free base). In examples, juvenile or adolescent patients weighing 10 kg to <15 kg are administered venelusstat or a pharmaceutically acceptable salt thereof at a dose of about 4 mg / day (calculated as free base), for example, as a once-daily dose of a tablet containing 4 mg venelusstat (calculated as free base). In the examples, juvenile or adolescent patients weighing 15 kg to < 30 kg were given venelusstat or a pharmaceutically acceptable salt thereof at a dose of about 6 mg / day (calculated as free base), for example as a once-daily dose of tablets containing 6 mg venelusstat (calculated as free base). In the examples, juvenile or adolescent patients weighing 30 kg to < 50 kg were given venelusstat or a pharmaceutically acceptable salt thereof at a dose of about 12 mg / day (calculated as free base), for example as a once-daily dose of two tablets each containing 6 mg venelusstat (calculated as free base). In the examples, juvenile or adolescent patients weighing ≥ 50 kg were given venelusstat or a pharmaceutically acceptable salt thereof at a dose of about 15 mg / day (calculated as free base), for example as a once-daily dose of tablets containing 15 mg venelusstat (calculated as free base).
[0088] In the embodiments, venlulstat is in the form of a free venlulstat base, a pharmaceutically acceptable salt of venlulstat, or a prodrug of venlulstat as described herein. In one embodiment, venlulstat is in the form of venlulstat malate, such as venlulstat L-malate, optionally in crystalline form.
[0089] In the examples, venulstat or a pharmaceutically acceptable salt thereof was administered in the form of a pharmaceutical composition as described herein.
[0090] In some examples, venelusstat or a pharmaceutically acceptable salt thereof is co-administered with a therapy for treating ganglioside storage disorders. In some examples, venelusstat or a pharmaceutically acceptable salt thereof is co-administered with enzyme replacement therapy (e.g., using β-aminohexosidase, neuraminidase, or β-galactosidase), gene therapy (e.g., introduction of HEXA and / or HEXB, NEU1, or GLB1), substrate reduction therapy using another SRT agent, pharmacological companion therapy, or stem cell therapy. In some examples, venelusstat or a pharmaceutically acceptable salt thereof is administered simultaneously (e.g., in the same oral dosage form) or separately (e.g., in different pharmaceutical compositions or dosage forms) with co-administered therapies.
[0091] In this embodiment, ganglioside storage disorder is a disorder that leads to the accumulation of GM1, GM2, and / or GM3 in the tissues and / or biological fluids of a human subject. In this embodiment, GM1, GM2, and / or GM3 are the major storing lipids associated with the disorder. In this embodiment, the patient has higher than normal levels of GM1, GM2, and / or GM3 in their CSF and / or blood (e.g., plasma). Normal levels can be assessed, for example, as described herein (see, for example, Example 4). In this embodiment, the ganglioside storage disorder is selected from GM2 ganglioside storage disorders (e.g., Sandhoff's disease or Tay-Sachs disease), GM1 ganglioside storage disorders, and sialic acid storage disorders (e.g., type I sialic acid storage disorders). In this embodiment, the ganglioside storage disorder is selected from GM2 ganglioside storage disorders (e.g., Sandhoff's disease or Tay-Sachs disease) and GM1 ganglioside storage disorders. In this embodiment, the ganglioside storage disorder is juvenile GM2 ganglioside storage disorder.
[0092] GM2 ganglioside storage syndrome
[0093] GM2 ganglioside storage disorders are a group of conditions characterized by the accumulation of GM2 in the body, particularly within neurons. GM2 ganglioside storage disorders are typically caused by pathogenic mutations in the HEXA and / or HEXB genes, leading to a deficiency of β-aminohexosidase activity. Symptoms can appear in infancy (acute infantile GM2 ganglioside storage disorders, where symptoms typically appear in the first 6 months of life), early childhood (subacute juvenile GM2 ganglioside storage disorders, where symptoms typically appear between 2 and 10 years of age), or later adolescence or adulthood (chronic adult GM2 ganglioside storage disorders). Late-onset GM2 ganglioside storage disorders, in particular, are often unrecognized or misdiagnosed due to their rarity (see, for example, Lopshire et al., Mol Genet Metab Rep [Molecular Genetics Metabolism Reports] (2023) 37:e1-e8). Juvenile GM2 ganglioside storage disorders typically differ from adult GM2 in their impact on cognitive function (see, for example, Maegawa et al., Pediatrics [Pediatrics] (2006) 118(5):e1550-e1562).
[0094] This study indicates that administration of venollustat to patients with GM2 ganglioside storage disorder can lead to a significant reduction in disease biomarkers (especially GM2) in CSF and plasma. Plasma biomarkers decreased to levels within the range shown in Table 1 below (indicating biomarker levels in healthy subjects), while CSF biomarker levels were also reduced.
[0095] Therefore, in one aspect or embodiment, this disclosure provides a method for reducing the level of a biomarker in the biological fluid of a human subject in need of GM2 ganglioside storage disease, the method comprising administering to the subject an effective amount of venelulstat or a pharmaceutically acceptable salt thereof, wherein the biomarker is GM2, optionally in combination with GM3 and / or GL1. In a related aspect or embodiment, this disclosure provides venelulstat or a pharmaceutically acceptable salt thereof for use in a method for reducing the level of a biomarker in the biological fluid of a human subject in need of GM2 ganglioside storage disease, wherein the biomarker is GM2, optionally in combination with GM3 and / or GL1. In another related aspect or embodiment, this disclosure provides the use of venelulstat or a pharmaceutically acceptable salt thereof in the preparation of a medicament for use in a method for reducing the level of a biomarker in the biological fluid of a human subject in need of GM2 ganglioside storage disease, wherein the biomarker is GM2, optionally in combination with GM3 and / or GL1.
[0096] On the other hand, this disclosure provides a method for administering venulstat or a pharmaceutically acceptable salt thereof to a subject in need suffering from GM2 ganglioside storage disorder, wherein venulstat or a pharmaceutically acceptable salt thereof is administered in an effective amount to reduce the level of a biomarker in the subject's biological fluid, wherein the biomarker is GM2, optionally in combination with GM3 and / or GL1.
[0097] In another aspect or embodiment, this disclosure provides a method for treating a subject in need of GM2 ganglioside storage disorder, the method comprising administering to the subject an effective amount of venelulstat or a pharmaceutically acceptable salt thereof, wherein the administration reduces the level of a biomarker in the subject's biological fluid, wherein the biomarker is GM2, optionally in combination with GM3 and / or GL1. In a related aspect or embodiment, this disclosure provides venelulstat or a pharmaceutically acceptable salt thereof for use in a method for treating a subject in need of GM2 ganglioside storage disorder, the method comprising administering to the subject an amount of venelulstat or a pharmaceutically acceptable salt thereof that effectively reduces the level of a biomarker in the subject's biological fluid, wherein the biomarker is GM2, optionally in combination with GM3 and / or GL1. In another relevant aspect or embodiment, this disclosure provides the use of venollustat or a pharmaceutically acceptable salt thereof in the preparation of an agent for use in a method of treating a subject of need suffering from GM2 ganglioside storage disorder, the method comprising administering to the subject an amount of venollustat or a pharmaceutically acceptable salt thereof that effectively reduces the level of a biomarker in the subject's biological fluid, wherein the biomarker is GM2, optionally in combination with GM3 and / or GL1.
[0098] It should be understood that the embodiments described above (e.g., related to methods for reducing biomarker levels in subjects with ganglioside storage disorders) can be applied to methods for reducing biomarker levels in subjects with GM2 ganglioside storage disorders. Further embodiments are listed below.
[0099] In this embodiment, GM2 ganglioside storage disease is selected from Tay-Sachs disease and Sandhoff disease. In this embodiment, GM2 ganglioside storage disease is selected from adult (or chronic late-onset) Tay-Sachs disease and adult (or chronic late-onset) Sandhoff disease. In this embodiment, GM2 ganglioside storage disease is juvenile GM2 ganglioside storage disease. In this embodiment, the subject has an aminohexosidase (e.g., β-aminohexosidase A or β-aminohexosidase B) activity level below about 0.6 IU / L (e.g., below about 0.5, 0.4, 0.3, 0.2, or 0.1 IU / L) at baseline. In the examples, the subjects had an aminohexosidase (e.g., β-aminohexosidase A or β-aminohexosidase B) activity level below about 0.10 IU / L at baseline (e.g., below about 0.08, 0.06, 0.04, 0.02, or 0.01 IU / L). In the examples, the subjects had an aminohexosidase (e.g., β-aminohexosidase A or β-aminohexosidase B) activity level that was undetectable at baseline. In the examples, administration of venulister or a pharmaceutically acceptable salt thereof reduced (or effectively reduced) plasma GM2 levels to between about 200 ng / mL and about 750 ng / mL.
[0100] In the embodiments, GM2 ganglioside storage disease is Tay-Sachs disease, and administration of venulister or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) GM2 levels in CSF by at least about 30%, for example at least about 40%, 50%, 60%, or 70%. In the embodiments, GM2 ganglioside storage disease is Tay-Sachs disease, and administration of venulister or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) GM2 levels in plasma by at least about 40%, for example at least about 50%, 60%, 70%, or 80%. In the example, GM2 ganglioside storage disease is Tay-Sachs disease, and administration of venulilstat or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) plasma GM2 levels to levels below about 750 ng / mL, below about 600 ng / mL, below about 500 ng / mL, below about 400 ng / mL, below about 300 ng / mL, or below about 250 ng / mL.
[0101] In the embodiments, GM2 ganglioside storage disease is Sandhoff's disease, and the administration of venulostat or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) GM2 levels in CSF by at least about 40%, for example at least about 50%, 60%, or 70%. In the embodiments, GM2 ganglioside storage disease is Sandhoff's disease, and the administration of venulostat or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) GM2 levels in plasma by at least about 40%, for example at least about 50%, 60%, 70%, 80%, or 90%. In the example, GM2 ganglioside storage disease is Sandhoff's disease, and administration of venulilstat or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) plasma GM2 levels to levels below about 750 ng / mL, below about 600 ng / mL, below about 500 ng / mL, below about 400 ng / mL, below about 300 ng / mL, or below about 200 ng / mL.
[0102] In the examples, GM2 ganglioside storage disease is juvenile GM2 ganglioside storage disease, and administration of venelusstat or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) GM2 levels in CSF by at least about 30%, for example at least about 40%, 50%, 60%, or 70%. In the examples, GM2 ganglioside storage disease is juvenile GM2 ganglioside storage disease, and administration of venelusstat or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) GM2 levels in plasma by at least about 40%, for example at least about 50%, 60%, 70%, or 80%. In the examples, GM2 ganglioside storage disease is juvenile GM2 ganglioside storage disease, and administration of venlustat or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) plasma GM2 levels to levels below about 750 ng / mL, below about 600 ng / mL, below about 500 ng / mL, below about 400 ng / mL, below about 300 ng / mL, or below about 250 ng / mL.
[0103] GM1 ganglioside storage syndrome
[0104] GM1 ganglioside storage disorder is typically caused by a pathogenic mutation in the GLB1 gene that results in a deficiency of β-galactosidase activity and the accumulation of GM1 in the body, particularly in neuronal tissue. Similar to GM2 ganglioside storage disorder, symptoms can appear in infancy, early childhood, or later adolescence or adulthood. However, the disorder can be considered as a range of symptoms related to residual enzyme activity (see, for example, Nicoli et al., Frontiers in Genetics (2021) 12:e1-e11).
[0105] This study indicates that administration of venollustat to patients with GM1 ganglioside storage disorder can lead to a significant reduction in CSF and plasma disease biomarkers, particularly GM1. CSF and plasma biomarkers in most subjects decreased to levels within the range shown in Table 1 below (indicating biomarker levels in healthy subjects).
[0106] Therefore, in one aspect or embodiment, this disclosure provides a method for reducing the level of a biomarker in the biological fluid of a human subject in need of GM1 ganglioside storage disease, the method comprising administering to the subject an effective amount of venelulstat or a pharmaceutically acceptable salt thereof, wherein the biomarker is GM1, optionally in combination with GM3 and / or GL1. In a related aspect or embodiment, this disclosure provides venelulstat or a pharmaceutically acceptable salt thereof for use in a method for reducing the level of a biomarker in the biological fluid of a human subject in need of GM1 ganglioside storage disease, wherein the biomarker is GM1, optionally in combination with GM3 and / or GL1. In another related aspect or embodiment, this disclosure provides the use of venelulstat or a pharmaceutically acceptable salt thereof in the preparation of a medicament for use in a method for reducing the level of a biomarker in the biological fluid of a human subject in need of GM1 ganglioside storage disease, wherein the biomarker is GM1, optionally in combination with GM3 and / or GL1.
[0107] On the other hand, this disclosure provides a method for administering venulstat or a pharmaceutically acceptable salt thereof to a subject in need suffering from GM1 ganglioside storage disorder, wherein venulstat or a pharmaceutically acceptable salt thereof is administered in an effective amount to reduce the level of a biomarker in the subject's biological fluid, wherein the biomarker is GM1, optionally in combination with GM3 and / or GL1.
[0108] In another aspect or embodiment, this disclosure provides a method for treating a subject in need of GM1 ganglioside storage disorder, the method comprising administering to the subject an effective amount of venelulstat or a pharmaceutically acceptable salt thereof, wherein the administration reduces the level of a biomarker in the subject's biological fluid, wherein the biomarker is GM1, optionally in combination with GM3 and / or GL1. In a related aspect or embodiment, this disclosure provides venelulstat or a pharmaceutically acceptable salt thereof for use in a method for treating a subject in need of GM1 ganglioside storage disorder, the method comprising administering to the subject an amount of venelulstat or a pharmaceutically acceptable salt thereof that effectively reduces the level of a biomarker in the subject's biological fluid, wherein the biomarker is GM1, optionally in combination with GM3 and / or GL1. In another relevant aspect or embodiment, this disclosure provides the use of venollustat or a pharmaceutically acceptable salt thereof in the preparation of an agent for use in a method of treating a subject of need suffering from GM1 ganglioside storage disorder, the method comprising administering to the subject an amount of venollustat or a pharmaceutically acceptable salt thereof that effectively reduces the level of a biomarker in the subject's biological fluid, wherein the biomarker is GM1, optionally in combination with GM3 and / or GL1.
[0109] It should be understood that the embodiments described above (e.g., related to methods for reducing biomarker levels in subjects with ganglioside storage disorders) can be applied to methods for reducing biomarker levels in subjects with GM1 ganglioside storage disorder. Further embodiments are listed below.
[0110] In the embodiments, administration of venelusstat or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) GM1 levels in CSF by at least about 30%, for example at least about 40%, 50%, 60%, or 70%. In the embodiments, administration of venelusstat or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) GM1 levels in plasma by at least about 40%, for example at least about 50%, 60%, or 70%.
[0111] In the examples, administration of venelusstat or a pharmaceutically acceptable salt thereof reduced (or effectively reduced) GM1 levels in CSF to levels below about 70 ng / mL, below about 65 ng / mL, below about 60 ng / mL, below about 55 ng / mL, below about 50 ng / mL, below about 45 ng / mL, or below about 40 ng / mL. In the examples, administration of venelusstat or a pharmaceutically acceptable salt thereof reduced (or effectively reduced) GM1 levels in plasma to levels between about 40 ng / mL and about 115 ng / mL. In the examples, administration of venelusstat or a pharmaceutically acceptable salt thereof reduced (or effectively reduced) GM1 levels in plasma to levels below about 120 ng / mL, below about 100 ng / mL, below about 90 ng / mL, below about 80 ng / mL, or below about 75 ng / mL.
[0112] Sialic acid storage syndrome
[0113] Sialic acid storage disorders are typically caused by a pathogenic mutation in the NEU1 gene, which leads to a deficiency of neuraminidase-1 activity and the accumulation of oligosaccharides and sialylated glycoproteins in the body. Sialic acid storage disorders are a heterogeneous disorder with varying ages of onset and pathologies, and there is currently no approved therapeutic treatment.
[0114] This study indicates that GM3 is one of the oligosaccharides that can accumulate in the biological fluids of patients with sialic acid storage disease. Administration of venlustat to patients with type I sialic acid storage disease resulted in a reduction in disease biomarkers (especially GM3) in CSF and plasma. CSF biomarkers decreased to levels within the range shown in Table 1 below (indicating biomarker levels in healthy subjects), while plasma biomarkers decreased to levels below the range shown in Table 1.
[0115] Therefore, in one aspect or embodiment, this disclosure provides a method for reducing the level of a biomarker in the biological fluid of a human subject in need of sialic acid storage disease (e.g., type I sialic acid storage disease), the method comprising administering to the subject an effective amount of venollustat or a pharmaceutically acceptable salt thereof, wherein the biomarker is GM3, optionally in combination with GM2 and / or GL1. In a related aspect or embodiment, this disclosure provides venollustat or a pharmaceutically acceptable salt thereof for use in a method for reducing the level of a biomarker in the biological fluid of a human subject in need of sialic acid storage disease (e.g., type I sialic acid storage disease), wherein the biomarker is GM3, optionally in combination with GM2 and / or GL1. In another relevant aspect or embodiment, this disclosure provides the use of venulister or a pharmaceutically acceptable salt thereof in the preparation of an agent for use in a method of reducing the level of a biomarker in a biological fluid of a human subject in need of suffering from sialic acid storage (e.g., type I sialic acid storage), wherein the biomarker is GM3, optionally in combination with GM2 and / or GL1.
[0116] On the other hand, this disclosure provides a method for administering venollustat or a pharmaceutically acceptable salt thereof to a subject in need of sialic acid storage, wherein venollustat or a pharmaceutically acceptable salt thereof is administered in an effective amount to reduce the level of a biomarker in the subject's biological fluid, wherein the biomarker is GM3, optionally in combination with GM2 and / or GL1.
[0117] In another aspect or embodiment, this disclosure provides a method for treating a subject in need of sialic acid storage disease (e.g., type I sialic acid storage disease), the method comprising administering to the subject an effective amount of venelusstat or a pharmaceutically acceptable salt thereof, wherein the administration reduces the level of a biomarker in the subject's biological fluid, wherein the biomarker is GM3, optionally in combination with GM2 and / or GL1. In a related aspect or embodiment, this disclosure provides venelusstat or a pharmaceutically acceptable salt thereof for use in a method for treating a subject in need of sialic acid storage disease (e.g., type I sialic acid storage disease), the method comprising administering to the subject an amount of venelusstat or a pharmaceutically acceptable salt thereof that effectively reduces the level of a biomarker in the subject's biological fluid, wherein the biomarker is GM3, optionally in combination with GM2 and / or GL1. In another relevant aspect or embodiment, this disclosure provides the use of venollustat or a pharmaceutically acceptable salt thereof in the preparation of an agent for use in a method for treating a subject of need suffering from sialic acid storage disorder (e.g., type I sialic acid storage disorder), the method comprising administering to the subject an amount of venollustat or a pharmaceutically acceptable salt thereof that effectively reduces the level of a biomarker in the subject's biological fluid, wherein the biomarker is GM3, optionally in combination with GM2 and / or GL1.
[0118] It should be understood that the embodiments described above (e.g., related to methods for reducing biomarker levels in human subjects with ganglioside storage disorders) can be applied to methods for reducing biomarker levels in human subjects with sialic acid storage disorders. Further embodiments are listed below.
[0119] In the embodiments, administration of venelusstat or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) GM3 levels in CSF by at least about 40%, for example at least about 50%, 60%, 70%, or 80%. In the embodiments, administration of venelusstat or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) GM3 levels in plasma by at least about 40%, for example at least about 50%, 60%, or 70%.
[0120] In the examples, administration of venelusstat or a pharmaceutically acceptable salt thereof reduced (or effectively reduced) the level of GM3 in CSF to below about 30 ng / mL, below about 25 ng / mL, below about 20 ng / mL, or below about 15 ng / mL. In the examples, administration of venelusstat or a pharmaceutically acceptable salt thereof reduced (or effectively reduced) the level of GM3 in CSF to between about 15 ng / mL and about 30 ng / mL. In the examples, administration of venelusstat or a pharmaceutically acceptable salt thereof reduced (or effectively reduced) the level of GM3 in plasma to below about 7.0 µg / mL, below about 6.5 µg / mL, below about 6.0 µg / mL, below about 5.5 µg / mL, below about 5.0 µg / mL, below about 4.5 µg / mL, or below about 4.0 µg / mL. In the examples, administration of venulostatine or a pharmaceutically acceptable salt thereof reduced (or effectively reduced) plasma GM3 levels to between approximately 5 µg / mL and approximately 20 µg / mL.
[0121] Reduction of disease-related proteins in CSF
[0122] The studies described in the examples below include analyses of disease-related protein levels in the CSF of patients (children and adults) with GM1 ganglioside storage disease and GM2 ganglioside storage disease. Results from these studies showed reduced CD63 and / or NFL levels in certain patient groups who received venulostat within 104 weeks.
[0123] CD63 is a cell surface glycoprotein that was first detected as a marker of platelet activation. In vivo, CD63 is localized to the membranes of melanosomes and platelet compacts. Some cells are rich in CD63, such as activated basophils and proliferating mast cells, and CD63 is commonly used in cell biology as a marker of late endocytic compartments. Recently, based on observations in patients with, for example, Gaucher disease and mucopolysaccharidosis (types I and II), CD63 has been proposed as a biomarker for a variety of lysosomal storage diseases. Compared with healthy controls, CD63 levels were found to be significantly increased in CSF samples taken from those patients, and / or decreased over time when patients received treatment (see, for example, International Patent Application No. PCT / IB2023 / 057323, published as WO 2024 / 018382, the contents of which are hereby incorporated by reference in their entirety). Neurofilament light chain protein (NFL) is the light subunit of neurofilament protein and a major structural component of myelin axons. CSF measurement in NFL is known to be an indicator of axonal damage in a variety of neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis and multiple sclerosis (see, for example, Bridel et al., JAMA Neurol. [Journal of American Medical Association Neurology] (2019) 76(9):1035-1048).
[0124] The reduction of CD63 in CSF
[0125] Therefore, in embodiments, this disclosure provides a method for reducing the level of biomarkers as described herein, wherein the method also reduces the level of CD63 in the CSF of a subject in need of having a ganglioside storage disorder, wherein the ganglioside storage disorder is GM2 ganglioside storage disorder.
[0126] In other embodiments, this disclosure provides a method of administering venollustat or a pharmaceutically acceptable salt thereof as described herein, wherein administering venollustat or a pharmaceutically acceptable salt thereof in an effective amount also reduces CD63 levels in the CSF of a subject in need suffering from a ganglioside storage disorder, wherein the ganglioside storage disorder is GM2 ganglioside storage disorder.
[0127] In other embodiments, this disclosure provides a method of treating a human subject as described herein, wherein administration of an effective amount of venlustat or a pharmaceutically acceptable salt thereof also reduces CD63 levels in the CSF of a subject in need suffering from a ganglioside storage disorder, wherein the ganglioside storage disorder is GM2 ganglioside storage syndrome.
[0128] In the examples, GM2 ganglioside storage disease is adult (or chronic late-onset) Tay-Sachs disease or adult (or chronic late-onset) Sandhoff disease, and administration of venulister or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) CD63 levels in the CSF by at least about 10%, for example, at least about 15%, 20%, 35%, 30%, 35%, or 40%. In the examples, GM2 ganglioside storage disease is juvenile GM2 ganglioside storage disease, and administration of venulister or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) CD63 levels in the CSF by at least about 10%, for example, at least about 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%. In the embodiments, the aforementioned reduction in CD63 levels in the CSF occurs within a period of approximately 12 weeks from the start of venulister administration, or within a period of at least approximately 12, 16, 24, 30, 40, 52, or 104 weeks from the start of venulister administration.
[0129] It should be understood that this disclosure also provides venulilstat or a pharmaceutically acceptable salt thereof for use in the methods according to the foregoing embodiments. This disclosure further provides the use of venulilstat or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical agent for use in the methods according to the foregoing embodiments.
[0130] The reduction of NFL in CSF
[0131] In embodiments, this disclosure provides a method for reducing the levels of biomarkers as described herein, wherein the method also reduces the level of NFL in the CSF of a subject in need of having a ganglioside storage disorder, wherein the ganglioside storage disorder is juvenile GM2 ganglioside storage disorder.
[0132] In other embodiments, this disclosure provides a method of administering venollustat or a pharmaceutically acceptable salt thereof as described herein, wherein administering venollustat or a pharmaceutically acceptable salt thereof in an effective amount also reduces NFL levels in the CSF of a subject in need suffering from ganglioside storage disorder, wherein ganglioside storage disorder is juvenile GM2 ganglioside storage disorder.
[0133] In other embodiments, this disclosure provides a method of treating a human subject as described herein, wherein administration of an effective amount of venlustat or a pharmaceutically acceptable salt thereof also reduces NFL levels in the CSF of a subject in need suffering from ganglioside storage disorder, wherein ganglioside storage disorder is juvenile GM2 ganglioside storage disorder.
[0134] In the embodiments, administration of venollustat or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) NFL levels in CSF by at least about 20%, for example at least about 30%, 40%, 50%, 60%, or 70%. In the embodiments, the aforementioned reduction in NFL levels in CSF occurs over a period of about 12 weeks from the start of venollustat administration, or over a period of at least about 12, 16, 24, 30, 40, 52, or 104 weeks from the start of venollustat administration.
[0135] It should be understood that this disclosure also provides venulilstat or a pharmaceutically acceptable salt thereof for use in the methods according to the foregoing embodiments. This disclosure further provides the use of venulilstat or a pharmaceutically acceptable salt thereof in the preparation of pharmaceutical agents for use in the methods according to the foregoing embodiments.
[0136] Venus Steratus
[0137] This disclosure takes into account salt forms of venulostat, such as venulostat in pharmaceutically acceptable salt forms.
[0138] Compounds that are fundamentally basic are generally capable of forming a wide variety of different salts with a variety of inorganic and / or organic acids. While such salts are generally pharmaceutically acceptable for administration to animals and humans, in practice it is often desirable to initially isolate the compound as a pharmaceutically unacceptable salt from the reaction mixture and then simply convert it back to a free basic compound by treatment with a basic reagent, followed by conversion of the free base into a pharmaceutically acceptable acid addition salt. Acid addition salts of basic compounds can be readily prepared using conventional techniques, for example, by treating the basic compound in an aqueous solvent medium or in a suitable organic solvent (e.g., methanol or ethanol) with substantially equal amounts of a chosen inorganic or organic acid. After careful evaporation of the solvent, the desired solid salt is obtained. Positively charged compounds (e.g., those containing quaternary ammonium) can also form salts with the anionic components of a variety of inorganic and / or organic acids.
[0139] The acids that can be used to prepare pharmaceutically acceptable venulostatine salts are those that can form non-toxic acid addition salts, such as salts containing pharmacologically acceptable anions, such as chlorides, bromides, iodides, nitrates, sulfates or bisulfates, phosphates or acidic phosphates, acetates, lactates, citrates or acidic citrates, tartrates or bitartrates, succinates, malates, maleates, fumarates, gluconates, sucrates, benzoates, methanesulfonates, and bis(hydroxynaphthyl)ate [i.e., 1,1'-methylene-bis(2-hydroxy-3-naphthylcarbamate)].
[0140] In one embodiment, a pharmaceutically acceptable salt is a succinate. In another embodiment, a pharmaceutically acceptable salt is a 2-hydroxysuccinate, such as (S)-2-hydroxysuccinate. In yet another embodiment, a pharmaceutically acceptable salt is a hydrochloride (i.e., a salt containing HCl). In yet another embodiment, a pharmaceutically acceptable salt is a malate, such as L-malate.
[0141] This disclosure also considers prodrugs of venuellustat. Pharmaceutically acceptable prodrugs disclosed herein are derivatives of venuellustat that can be converted in vivo. These prodrugs may possess some activity on their own, and they become pharmaceutically active in vivo when they undergo solvent degradation or enzymatic degradation under physiological conditions, for example. Based on this disclosure, methods for preparing prodrugs of venuellustat will be clear to those skilled in the art.
[0142] In one embodiment, the venulshurtate carbamate moiety is modified. For example, the carbamate moiety moiety can be modified by adding water and / or one or two aliphatic alcohols. In this case, the carbon-oxygen double bond of the carbamate moiety moiety adopts a substance that can be considered a hemiacetal or acetal functional group. In one embodiment, the carbamate moiety moiety can be modified by adding an aliphatic diol (such as 1,2-ethylene glycol).
[0143] In one embodiment, the amino group on the quinine ring moiety is modified. For example, the amino group can be modified to form an acid derivative or a quaternary ammonium salt. The derivative can be formed, for example, by reacting venollustat with an acetylation agent (such as an acyl chloride) or with an agent (such as an alkyl halide).
[0144] This disclosure further includes hydrates, solvates, and polymorphs of venulstat. For example, venulstat can be in one or more crystalline forms as described, for example, in International Patent Application No. PCT / US2014 / 027081 (published as WO 2014 / 152215), the entire contents of which are incorporated herein by reference. In embodiments, venulstat is in the form of malate and in crystalline form A as described in WO 2014 / 152215 (see, for example, claims 1-6). In other embodiments, venulstat is in the form of malate and in crystalline form B as described in WO 2014 / 152215 (see, for example, claims 7-12).
[0145] Isotope-labeled compounds are also within the scope of this disclosure. As used herein, "isotope-labeled compound" refers to the compounds disclosed herein, including their respective pharmaceutical salts and prodrugs as described herein, wherein one or more atoms are replaced by atoms with atomic masses or mass numbers different from those normally found in nature. Examples of isotopes that may be incorporated into the compounds disclosed herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as... 2 H, 3 H, 13 C 14 C 15 N、 18 O、 17 O、 31 P, 32 P, 35 S, 18 F and 36 Cl.
[0146] Pharmaceutical Composition
[0147] Venrolstat or a pharmaceutically acceptable salt thereof used according to this disclosure can be formulated as a pharmaceutical composition. Therefore, this disclosure provides a pharmaceutical composition (e.g., an oral dosage form) comprising venrolstat or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. The composition may be particularly suitable for use in any of the methods disclosed herein.
[0148] Pharmaceutically acceptable excipients can be any such excipients known in the art, including, for example, those described in Remington's Pharmaceutical Sciences, Mack Publishing Co. (AR Gennaro, ed. 1985). Pharmaceutical compositions of the compounds disclosed herein can be prepared by conventional means known in the art, including, for example, mixing at least one of the disclosed compounds with a pharmaceutically acceptable excipient.
[0149] In some embodiments, venlulstat is in a solid crystalline form (e.g., crystalline malate form A of venlulstat). In other embodiments, the venlulstat is in a solid amorphous form. In some embodiments, the dosage form comprises an amorphous solid dispersion containing venlulstat and pharmaceutically acceptable excipients.
[0150] In the embodiments, the dosage form is a capsule (e.g., a hard capsule) or a tablet (e.g., a chewable tablet, an orally disintegrating tablet, a dispersible tablet, or a classic tablet or capsule), optionally said dosage form comprising from about 2 mg to about 30 mg of venollustat (measured in the equivalent of free base), such as from about 4 mg to about 20 mg, or from about 8 mg to about 12 mg, or about 4 mg, or about 6 mg, or about 8 mg, or about 12 mg, or about 15 mg of venollustat (measured in the equivalent of free base).
[0151] In the examples, the dosage form is a classic tablet or capsule (e.g., for swallowing), chewable tablet, orally disintegrating tablet, or dispersible tablet.
[0152] In the embodiments, pharmaceutically acceptable excipients comprise one or more of the following: (a) diluents / fillers (e.g., cellulose or microcrystalline cellulose, mannitol or lactose), (b) binders (e.g., povidone, methylcellulose, ethylcellulose, hydroxypropylcellulose (such as low-substituted hydroxypropylcellulose) or hydroxypropyl methylcellulose), (c) disintegrants (e.g., cropovidone, sodium starch glycolate or croscarmellose sodium), (d) lubricants (e.g., magnesium stearate or sodium stearoyl fumarate), (e) flow aids (e.g., silica or talc), (f) sweeteners (e.g., sucralose, acesulfame potassium, aspartame, saccharin, neotame or adventitia), (g) flavoring agents (e.g., apricot flavoring), and (h) dyes or coloring agents.
[0153] In the embodiments, pharmaceutically acceptable excipients comprise one or more hydrophilic, water-soluble, or water-swellable polymers. In the embodiments, the polymers are selected from the group consisting of natural or modified cellulose polymers or any mixture thereof.
[0154] In the embodiments, any one or more pharmaceutically acceptable excipients are present in amounts of 0.01% to 80% by weight, such as 0.1% to 60%, or 0.1% to 40%, or 0.1% to 30%, 0.01% to 15%, or 0.01% to 10%, or 0.1% to 20%, or 0.1% to 15%, or 0.1% to 10%, or 0.5% to 10%, or 0.5% to 5%, or 1% to 5%, or 2.5% to 5%, or 1% to 3%, or 0.1% to 1%. In embodiments, the dosage form comprises (a) one or more diluents / fillers in the range of 5%-95% by weight (e.g., 60%-70%, 70%-80%, 65%-75%, 65%-70%, or about 68%); (b) one or more lubricants in the range of 0.5%-5% by weight (e.g., 1%-5%, 2%-4%, 2%-3%, or about 3%); (c) one or more disintegrants in the range of 2%-15% by weight (e.g., 4%-12%, 6%-10%, 7%-9%, or about 8%); (d) one or more binders in the range of 0%-12% by weight (e.g., 2%-10%, 2%-8%, 3%-7%, 4%-6%, or about 5%); and (e) [other components not specified in the original text]. One or more gliding agents, by weight, comprising 0-5% (e.g., 0.15%-4%, or 1%-3%, or 1%-2%, or about 1%); and (f) one or more flavoring agents, one or more sweeteners, and / or one or more colorings, by weight, comprising 0-2%; for example, about 1% each of one or more flavoring agents, one or more sweeteners, and / or one or more colorings. In the embodiments, venulister is present in an amount of 3% to 20% by weight (measured as free base).
[0155] In the embodiments, the oral pharmaceutical composition is a pill, capsule, tablet, sugar-coated pill, powder, granule, film, lozenge, or liquid. In the embodiments, the oral pharmaceutical composition is a capsule or tablet, such as a tablet. In the embodiments, the oral pharmaceutical composition is a formulation as described below: International Patent Application No. PCT / IB2021 / 056673 (published as WO 2022 / 018695), the entire contents of which are incorporated herein by reference.
[0156] In this embodiment, the preparation is a capsule having the following ingredients:
[0157]
[0158] In the example, the capsule contained 15 mg of venlucalstat (20.16 mg of venlucalstat malate), the capsule had a filler mass of 165 mg, and the preparation was packaged into a size 3 capsule shell.
[0159] In other embodiments, the formulation is a tablet having the following components:
[0160]
[0161] In one embodiment, the tablet contains 15 mg of venelulstat (20.16 mg of venelulstat malate), the flavoring agent is apricot flavoring, and the tablet weighs 150 mg. In other embodiments, the tablet contains 6 mg of venelulstat (8.06 mg of venelulstat malate), the flavoring agent is apricot flavoring, and the tablet weighs 60 mg.
[0162] In the embodiments, the dosage form is a hard-shell capsule, for example, wherein the capsule contains a mixture of venulstat (e.g., venulstat malate) and one or more pharmaceutically acceptable excipients. Venulstat and other diluents / carriers may be in the form of granules or microcapsules, or in the form of powders, which are contained within the capsule shell.
[0163] The pharmaceutical compositions or dosage forms disclosed herein may include a pharmaceutical agent and another carrier, such as an inert or active compound or composition, such as a detectable agent, label, adjuvant, diluent, binder, stabilizer, buffer, salt, lipophilic solvent, preservative, adjuvant, etc. The carrier also includes pharmaceutical excipients and additives, such as proteins, peptides, amino acids, lipids, and carbohydrates (e.g., sugars, including monosaccharides, disaccharides, trisaccharides, tetrasaccharides, and oligosaccharides; derived sugars, such as sugar alcohols, aldonic acids, esterified sugars, etc.; and polysaccharides or sugar polymers), which may be present alone or in combination, comprising from 1% to 99.99% by weight or volume. Exemplary protein excipients include serum albumin, such as human serum albumin (HSA), recombinant human albumin (rHA), gelatin, casein, etc. Representative amino acid / antibody components (which may also function in buffering capacity) include alanine, glycine, arginine, betaine, histidine, glutamic acid, aspartic acid, cysteine, lysine, leucine, isoleucine, valine, methionine, phenylalanine, aspartame, etc. Carbohydrate excipients are also intended to be used within the scope of this disclosure, examples of which include, but are not limited to, monosaccharides such as fructose, maltose, galactose, glucose, D-mannose, sorbitol, etc.; disaccharides such as lactose, sucrose, trehalose, cellobiose, etc.; polysaccharides such as raffinose, melitriose, maltodextrin, dextran, starch, etc.; and sugar alcohols such as mannitol, xylitol, maltitol, lactitol, xylitol, sorbitol (glucosol), and inositol.
[0164] Suitable carriers include buffers or pH adjusters; typically, buffers are salts prepared from organic acids or bases. Representative buffers include organic acid salts such as citrate, ascorbate, gluconate, carbonate, tartrate, succinate, acetate, or phthalate; Tris, tromethamine hydrochloride, or phosphate buffers. Other carriers include polymeric excipients / additives such as polyvinylpyrrolidone, polysucrose (polymeric sugars), dextrates (e.g., cyclodextrins, such as 2-hydroxypropyl-β-cyclodextrin), polyethylene glycol, flavoring agents, antimicrobial agents, sweeteners, antioxidants, antistatic agents, surfactants (e.g., polysorbates, such as “TWEEN 20” and “TWEEN 80”), lipids (e.g., phospholipids, fatty acids), steroids (e.g., cholesterol), and chelating agents (e.g., EDTA).
[0165] In solid dosage forms intended for oral administration (e.g., capsules, tablets, pills, sugar-coated pills, powders, granules, etc.), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, excipients, or diluents, such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol, microcrystalline cellulose, calcium phosphate, and / or silica; (2) binders, such as carboxymethyl cellulose, alginate, gelatin, pregelatinized corn starch, polyvinylpyrrolidone, hydroxypropyl methylcellulose, sucrose, and / or gum arabic; (3) humectants, such as glycerin; (4) disintegrants, such as agar-agar, calcium carbonate, sodium starch glycolate, potato or cassava starch, alginate, certain silicates, and sodium carbonate; (5) solution blockers, such as paraffin; (6) absorption enhancers, such as quaternary ammonium compounds; (7) Wetting agents, such as sodium lauryl sulfate, acetyl alcohol, and glyceryl monostearate; (8) absorbents, such as kaolin and bentonite; (9) lubricants, such as talc, silica, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof; and (10) colorants. In the case of capsules, tablets, and pills, the pharmaceutical composition may also contain a buffer. Similar types of solid compositions can also be prepared using fillers and excipients (such as lactose or milk sugar and high molecular weight polyethylene glycol, etc.) found in soft-filled and hard-filled gelatin capsules.
[0166] Tablets can be prepared by compression or molding (optionally with one or more excipients). Compressed tablets can be prepared using binders (e.g., gelatin or hydroxypropyl methylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium starch glycolate or croscarmellose sodium), surfactants, and / or dispersants. Molded tablets can be prepared by molding a mixture of powdered active ingredients wetted with an inert liquid diluent in a suitable machine. Tablets and other solid dosage forms (such as sugar-coated pills, capsules, pellets, and granules) can optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings known in the art.
[0167] In the embodiments, the pharmaceutical composition is administered orally in liquid form. Liquid dosage forms for oral administration of the active ingredient include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. Liquid formulations for oral administration may be presented as dry products for preparation with water or other suitable media prior to use. In addition to the active ingredient, the liquid dosage form may contain inert diluents (e.g., water or other solvents), solubilizers, and emulsifiers commonly used in the art, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butanediol, oils (e.g., cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerin, tetrahydrofuranol, polyethylene glycol, and sorbitan fatty acid esters, and mixtures thereof. In addition to inert diluents, the liquid pharmaceutical composition may contain excipients such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents, coloring agents, fragrances, and preservatives. In addition to containing one or more active ingredients, suspensions may also contain suspending agents, such as, but not limited to, isostearyl alcohol oxyoxide, polyoxyethylene sorbitol and dehydrated sorbitol, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and astragalus gum, and mixtures thereof. Suitable liquid formulations may be prepared by conventional means with one or more pharmaceutically acceptable additives, such as suspending agents (e.g., sorbitol syrup, methylcellulose or hydrogenated edible fats); emulsifiers (e.g., lecithin or gum arabic); non-aqueous mediators (e.g., almond oil, esters or ethanol); and / or preservatives (e.g., methylparaben or propylparaben, or sorbic acid). One or more active ingredients may also be administered as pellets, syrups or pastes.
[0168] In some embodiments of the methods described herein, the pharmaceutical composition may be in the form of tablets or lozenges formulated for conventional buccal administration.
[0169] Controlled-release parenteral compositions may be in the following forms: aqueous suspensions, microspheres, microcapsules, magnetic microspheres, oil solutions, oil suspensions, emulsions, or the active ingredient may be incorporated into one or more biocompatible carriers, liposomes, nanoparticles, implants, or infusion devices. Materials used in the preparation of microspheres and / or microcapsules include, but are not limited to, biodegradable / biosoluble polymers such as poly(lactic-co-glycolic acid), poly(isobutyl cyanoacrylate), poly(2-hydroxyethyl-L-glutamine), and poly(lactic acid). Biocompatible carriers that may be used when formulating controlled-release parenteral preparations include carbohydrates (such as dextran), proteins (such as albumin), lipoproteins, or antibodies. Materials used in implants may be non-biodegradable (e.g., polydimethylsiloxane) or biodegradable (e.g., poly(caprolactone), poly(lactic acid), poly(glycolic acid), or poly(ortho-ester)).
[0170] For the determination of quantitative glycosphingolipid levels
[0171] The levels of biomarkers (e.g., one or more of sphingolipids GL1, GM1, GM2, and GM3) in biological fluids can be measured by methods known in the art (e.g., as described in the publications cited herein) or by methods detailed herein (e.g., in the examples below). In the examples, the levels of biomarkers are quantified using LC / MS / MS methods, for example, as described herein. In such methods, a fluid sample (e.g., human plasma or CSF) can be applied to a column (e.g., an HPLC or UPLC column) under conditions that facilitate the separation of glycosphingolipids from the sample. The resulting fractions can then be analyzed by mass spectrometry (e.g., by tandem MS / MS), and one or more peak areas for one or more subtypes of each target glycosphingolipid are calculated. The concentration of each target glycosphingolipid in the original sample can then be determined, for example, by comparison with a reference sample having a known concentration of a related glycosphingolipid.
[0172] In the examples, the sphingolipid is GL1, and the total concentration of GL1 is determined by summing the mass spectrometric intensities from the following isomers: GL1 16:0; GL1 18:0; GL1 20:0; GL1 22:0; GL1 23:0; GL1 24:1; and GL1 24:0. In the examples, the method uses N-octadecyl-D35-sphingosine galactoside as an internal standard (e.g., when measuring plasma GL1). In the examples, the method uses 13C6-glucosylceramide (13C-labeled C24:0 GL-1) as an internal standard (e.g., when measuring CSF GL1).
[0173] In the examples, the sphingolipid was GM1, and the total concentration of GM1 was determined by summing the mass spectrometric intensities from some or all of the following isomers: GM1 Cer34:1; GM1 Cer36:1; GM1 Cer38:1; GM1 Cer40:1; GM1 Cer42:1; and GM1 Cer42:2. In the examples, the method used N-hexadecyl-D9-monosialoganglioside GM1 as an internal standard.
[0174] In the examples, the sphingolipid was GM2, and the concentration of GM2 was determined by summing the mass spectrometric intensities from the following isomers: GM2 C16:0; GM2 C18:0; GM2 C20:0; GM2 C22:0; GM2 C23:0; GM2 C24:0; and GM2 C24:1. In the examples, the method used N-hexadecyl-D9-monosialidoganglioside GM2 as an internal standard.
[0175] In the examples, the sphingolipid is GM3, and the total concentration of GM3 is determined by summing the mass spectrometric intensities from the following isomers: GM3 C16:0; GM3 C18:0; GM3 C20:0; GM3 C22:0; GM3 C23:0; GM3 C24:0; and GM3 C24:1. In the examples, the method uses gangliotrisaccharide ceramide (GA2) as an internal standard (e.g., when measuring plasma GM3). In the examples, the method uses deuterated C16:0 GM3-[palmitoyl-D] 31 Used as an internal standard (e.g., when measuring CSF GM3).
[0176] The levels of disease-associated proteins (CD63 and / or NFL) in CSF can be measured by methods known in the art (e.g., as described in the publications cited herein) or by methods detailed herein (e.g., in the examples below). In the embodiments, the levels of disease-associated proteins are quantified using methods selected from: immunoassays (e.g., ELISA, microfluidic ELISA, or bead-based high-sensitivity ELISA; capillary blot assay; nanoneedle bioarray; proximity connectivity assay; or proximity extension assay), affinity-based assays (e.g., nucleic acid binding aptamer assay), or mass spectrometry.
[0177] The disclosure has been described in general in this document, and the following non-limiting examples are provided to illustrate this disclosure in one step.
[0178] Example
[0179] Example 1A: (S)-quininecyclo-3-yl-2-(2-(4-fluorophenyl)thiazolyl-4-yl)propyl-2-ylcarbamate (Text) Synthesis of rustatin
[0180] Ethyl 4-chloroacetoacetate (7.8 mL, 58 mmol) was added to a stirred solution of 4-fluorothiobenzamide (8.94 g, 57.6 mmol) in ethanol (70 mL). The reaction was heated under reflux for 4 h, treated with an aliquot of ethyl 4-chloroacetoacetate (1.0 mL, 7.4 mmol), and refluxed again for 3.5 h. The reaction was then concentrated and the residue was partitioned between ethyl acetate (200 mL) and an aqueous solution of NaHCO3 (200 mL). The back-extracts of the organic and aqueous layers (ethyl acetate, 1 x 75 mL) were combined, dried (Na2SO4), and concentrated. The resulting amber oil was purified by rapid chromatography using a hexane / ethyl acetate gradient to give ethyl 2-(2-(4-fluorophenyl)thiazolyl-4-yl)acetate (13.58 g, 89%) as a low-melting, almost colorless solid.
[0181] Sodium hydride [60% dispersion in mineral oil] (2.84 g, 71.0 mmol) was added to a stirred solution of ethyl 2-(2-(4-fluorophenyl)thiazol-4-yl)acetate (6.28 g, 23.7 mmol) in DMF (50 mL). The foam mixture was stirred for 15 minutes, then cooled in an ice bath and methyl iodide (4.4 mL, 71 mmol) was added. The reaction was stirred overnight, allowing the cooling bath to slowly warm to room temperature. The mixture was then concentrated and the residue was partitioned between ethyl acetate (80 mL) and water (200 mL). The organic layer was washed with a second portion of water (1 x 200 mL), dried (Na2SO4), and concentrated. The resulting amber oil was purified by rapid chromatography using a hexane / ethyl acetate gradient to give ethyl 2-(2-(4-fluorophenyl)thiazol-4-yl)-2-methylpropionate (4.57 g, 66%) as a colorless oil.
[0182] Lithium hydroxide monohydrate (2.93 g, 69.8 mmol) was added to a stirred solution of ethyl 2-(2-(4-fluorophenyl)thiazol-4-yl)-2-methylpropionic acid (4.56 g, 15.5 mmol) in a 1:1:1 THF / ethanol / water mixture (45 mL). The reaction was stirred overnight, concentrated, and redissolved in water (175 mL). The solution was washed with ether (1 x 100 mL), acidified by adding 1.0 N HCl (80 mL), and extracted with ethyl acetate (2 x 70 mL). The combined extracts were dried (Na₂SO₄) and concentrated to give 2-(2-(4-fluorophenyl)thiazol-4-yl)-2-methylpropionic acid (4.04 g, 98%) as a white solid. This material was used in the next step without purification.
[0183] Trimethylamine (4.2 mL, 30 mmol) was added to a solution of 2-(2-(4-fluorophenyl)thiazolyl-4-yl)-2-methylpropionic acid (4.02 g, 15.2 mmol) in THF (100 mL) under stirring and cooling (0°C), followed by the addition of isobutyl chloroformate (3.0 mL, 23 mmol). The reaction was then cooled and stirred for another 1 hour, followed by the addition of a solution of sodium azide (1.98 g, 30.5 mmol) in water (20 mL). The reaction was stirred overnight, allowing the cooling bath to slowly warm to room temperature. The mixture was then diluted with water (100 mL) and extracted with ethyl acetate (2 x 60 mL). The combined extracts were washed with an aqueous solution of NaHCO3 (1 x 150 mL) and brine (1 x 100 mL), dried (Na2SO4), and concentrated. After co-evaporation with toluene (2 x 50 mL), the resulting white solid was absorbed in toluene (100 mL) and refluxed for 4 hours. Then (S)-3-quininecyclool (3.87 g, 30.4 mmol) was added and reflux continued overnight. The reaction was concentrated and the residue was partitioned between ethyl acetate (100 mL) and an aqueous solution of NaHCO3 (150 mL). The organic layer was washed with water (1 x 150 mL), dried (Na2SO4), and concentrated. The resulting off-white solid was purified by rapid chromatography using a chloroform / methanol / ammonia gradient to give the title compound (4.34 g, 73%) as a white solid. 1 H NMR (400 MHz, CDCl3) δ 7.96-7.88 (m, 2H), 7.16-7.04 (m, 3H), 5.55 (br s, 1H), 4.69-4.62 (m, 1H), 3.24-3.11 (m, 1H), 3.00-2.50 (m, 5H),2.01-1.26 (m, 11H) ppm. 13 C10 NMR (400 MHz, CDCl3) δ 166.4, 165.1, 163.8 (d, J=250.3 Hz), 162.9, 155.0, 130.1 (d, J=3.3 Hz), 128.4 (d, J=8.5 Hz), 115.9 (d, J=22.3 Hz), 112.5, 71.2, 55.7, 54.2, 47.5, 46.5, 28.0, 25.5, 24.7, 19.6 ppm. Purity: 100% UPLCMS (210 nm and 254 nm); retention time 0.83 min; (M+1) 390.
[0184] Example 1B: (S)-quinine-3-yl(2-(2-(4-fluorophenyl)thiazolyl-4-yl)prop-2-yl)in the form of a free base Preparation of vinlustat (carbamate)
[0185] Step 1: Dimethylation with iodomethane
[0186]
[0187] The 3N RB flask was equipped with a thermometer, a feeding funnel, and a nitrogen inlet. The flask was rinsed with nitrogen, and potassium tert-butoxide (MW 112.21, 75.4 mmol, 8.46 g, 4.0 equivalent, white powder) was weighed and added to the flask via a powder funnel, followed by the addition of THF (60 mL). Most of the potassium tert-butoxide dissolved to give a turbid solution. The mixture was cooled to 0–2°C (internal temperature) in an ice-water bath. In a separate flask, the starting ester (MW 265.3, 18.85 mmol, 5.0 g, 1.0 equivalent) was dissolved in THF (18 mL + 2 mL as rinsing solution) and transferred to a feeding funnel. This solution was added dropwise to the cooled mixture over a period of 25–30 min, keeping the internal temperature below 5°C during the addition. The reaction mixture was cooled back to 0–2°C. In a separate flask, a solution of iodomethane (MW 141.94, 47.13 mmol, 6.7 g, 2.5 equivalents) in THF (6 mL) was prepared and transferred to a feeding funnel. The flask containing the iodomethane solution was then rinsed with THF (1.5 mL) and transferred to a feeding funnel containing a clear, colorless solution of iodomethane in THF. This solution was carefully added dropwise over a period of 30–40 min to the dark brown reaction mixture, keeping the internal temperature below 10°C throughout the addition. After the addition was complete, the slightly turbid mixture was stirred for another 1 h, during which time the internal temperature was lowered to 0–5°C. After stirring at 0–5°C for one hour, the reaction mixture was quenched over a period of 5–7 min by the slow dropwise addition of 5.0 M HCl aqueous solution (8 mL). During this addition, the internal temperature was maintained below 20°C. After the addition, water (14 mL) was added and the mixture was stirred for 2–3 min. Stirring was stopped and the two layers were allowed to separate. The two layers were then transferred to a 250 mL 1NRB flask, and the THF was evaporated as much as possible under vacuum to obtain a THF / product and water biphase layer. Separation of the two layers was allowed. The THF solution of the product from step 1 was used for the next reaction.
[0188] Step 2: Hydrolyze ethyl ester with LiOH monohydrate
[0189]
[0190] The crude ester in THF was added to the reaction flask. LiOH·H₂O (MW 41.96, 75.0 mmol, 3.15 g, 2.2 equivalents) was weighed separately in a 100 mL beaker (with a stir bar). Water (40 mL) was added and the mixture was stirred until all solids dissolved to obtain a clear, colorless solution. This aqueous solution was then added to a 250 mL RB flask containing the ester in tetrahydrofuran (THF). A condenser was attached to the neck of the flask, and a nitrogen inlet was attached to the top of the condenser. The mixture was heated under reflux for 16 hours. After 16 hours, heating was stopped, and the mixture was cooled to room temperature. THF was evaporated under vacuum to give a brown solution. The complete hydrolysis of ethyl ester in aliquots of the brown aqueous solution was analyzed by HPLC and LC / MS. Water (15 mL) was added, and this alkaline aqueous solution was extracted with TBME (2 x 40 mL) to remove tert-butyl ester. The alkaline aqueous layer was cooled to 0–10°C in an ice-water bath and acidified to approximately pH 1 by dropwise addition of concentrated HCl with stirring. TBME (60 mL) was added to the gelatinous solid in the acidic aqueous solution, and the mixture was shaken and then vigorously stirred to dissolve all the acid into the TBME layer. The two layers were transferred to a separatory funnel, and the TBME layer was separated. The pale yellow acidic aqueous solution was re-extracted with TBME (40 mL), and the TBME layer was separated and combined with the previous TBME layer. The acidic aqueous layer was discarded. The combined TBME layers were dried over anhydrous Na₂SO₄, filtered, and evaporated under vacuum to remove TBME, yielding a crude acid as an orange / deep yellow oil, which solidified into a dirty yellow solid under high vacuum. The crude acid was weighed and crystallized by heating in heptane / TBME (3:1, 5 mL / g crude) to give an acid as a yellow solid.
[0191] Step 3: Form hydroxylamine acid using NH2OH·HCl
[0192]
[0193] Formic acid (MW 265.3, 18.85 mmol, 5.0 g, 1.0 equivalent) was weighed and transferred to a 25 mL 1N RB flask under nitrogen atmosphere. THF (5.0 mL) was added and the acid was readily dissolved to obtain a clear, deep yellow to brown solution. The solution was cooled to 0–2°C in an ice bath, and N,N'-carbonyldiimidazole (CDI; MW 162.15, 20.74 mmol, 3.36 g, 1.1 equivalent) was added slowly in small amounts over 10–15 minutes. The ice bath was removed and the solution was stirred at room temperature for 1 h. After stirring for 1 h, the solution was cooled again to 0–2°C in an ice-water bath. Hydroxylamine hydrochloride (NH₂OH.HCl; MW 69.49, 37.7 mmol, 2.62 g, 2.0 equivalents) was added slowly in small amounts over a period of 3–5 minutes as the addition was exothermic. After the addition was complete, water (1.0 mL) was added dropwise to the heterogeneous mixture over a period of 2 minutes, and the reaction mixture was stirred in an ice-water bath at 0–10°C for 5 minutes. The cooling bath was removed, and the reaction mixture was stirred overnight at room temperature under nitrogen for 20–22 h. The solution became clear as all the NH₂OH.HCl dissolved. After 20–22 h, aliquots of the reaction mixture were analyzed by high-performance liquid chromatography (HPLC). THF was then evaporated under vacuum, and the residue was absorbed in dichloromethane (120 mL) and water (60 mL). The mixture was transferred to a separatory funnel, shaken, and allowed to separate into two layers. Discard the aqueous layer and wash the dichloromethane layer with 1 N hydrochloric acid (HCl; 60 mL). Discard the acid layer. Dry the dichloromethane layer with anhydrous Na₂SO₄, filter, and evaporate the solvent under vacuum to obtain crude hydroxylamine as a pale yellow solid, which is then dried under high vacuum overnight.
[0194] Continuation of step 3: Hydroxyamino acid is converted into a cyclic intermediate (not separated).
[0195]
[0196] Crude hydroxylamine (MW 280.32, 5.1 g) was transferred to a 250 mL 1N RB flask with a nitrogen inlet. A stir bar was added, followed by acetonitrile (50 mL). The solid was insoluble in acetonitrile. The yellow heterogeneous mixture was stirred under nitrogen for 2–3 min, and CDI (MW 162.15, 20.74 mmol, 3.36 g, 1.1 equivalent) was added in single-part batches at room temperature. No exothermic reaction was observed. The solid dissolved immediately, and the clear yellow solution was stirred at room temperature for 2–2.5 h. After 2–2.5 h, the aliquots were analyzed by HPLC and LC / MS, showing that the hydroxylamine was converted to the desired cyclic intermediate.
[0197] The acetonitrile was then evaporated under vacuum to give a coarse cyclic intermediate that was a slightly reddish, viscous oil. The oil was absorbed in toluene (60 mL) and the slightly reddish mixture was heated to reflux for 2 hours, during which time the cyclic intermediate released CO2 and rearranged into isocyanates (see below).
[0198]
[0199] Continuation of step 3: Isocyanate is converted into free base
[0200]
[0201] The reaction mixture was cooled to 50°C–60°C, and (S)-(+)-quininecyclool (MW 127.18, 28.28 mmol, 3.6 g, 1.5 equivalents) was added to the mixture as a solid in a single part. The mixture was then reheated to reflux for 18 h. After 18 h, analysis of the aliquots by HPLC and LC / MS showed complete conversion of the isocyanate to the desired product. The reaction mixture was transferred to a separatory funnel and toluene (25 mL) was added. The mixture was washed with water (2 x 40 mL) and the aqueous layer was separated. The combined aqueous layers were re-extracted with toluene (30 mL) and discarded. The combined toluene layers were extracted with 1 N HCl (2 x 60 mL) and discarded (containing O-acyl impurities). The combined HCl layers were transferred to a 500 mL Erlenmeyer flask equipped with a stir bar. The stirred, clear yellow / slightly red solution was alkalized to pH 10–12 by dropwise addition of 50% w / w NaOH aqueous solution. The desired free base precipitates from the solution, forming a dirty yellow gelatinous solid that can trap the stir bar. Isopropyl acetate (100 mL) is added to this mixture, and the mixture is vigorously stirred for 5 minutes as the gelatinous solid enters the isopropyl acetate. Stirring is stopped, and the two layers are allowed to separate. The yellow isopropyl acetate layer is separated, and the alkaline aqueous layer is re-extracted with isopropyl acetate (30 mL). The alkaline aqueous layer is discarded, and the combined isopropyl acetate layers are dried over anhydrous Na₂SO₄, filtered into a pre-weighed RB flask, and the solvent is evaporated under vacuum to obtain a crude free base as a beige to brownish-red solid, which is then dried under high vacuum overnight.
[0202] Continuation of step 3: recrystallization of crude free alkali
[0203] Weigh the beige to brownish-red crude free base and recrystallize it from heptane / isopropyl acetate (3:1, 9.0 mL solvent per gram of crude free base). Add an appropriate amount of heptane / isopropyl acetate to the crude free base along with a stir bar, and heat the mixture to reflux for 10 min (the free base is initially partially soluble but dissolves upon reflux to give a clear, slightly reddish solution). Remove the heat source, and allow the mixture to cool to room temperature with stirring as a white precipitate forms. After stirring at room temperature for 3–4 h, filter the precipitate through a Buchner funnel under vacuum, wash with heptane (20 mL), and dry overnight in a Buchner funnel under vacuum. Transfer the precipitate to a crystallizing dish and dry overnight in a vacuum oven at 55°C. 1 H NMR (400 MHz, CDCl3) δ 8.04 – 7.83 (m, 2H), 7.20 – 6.99 (m,3H), 5.53 (s, 1H), 4.73 – 4.55 (m, 1H), 3.18 (dd, J = 14.5, 8.4 Hz, 1H), 3.05–2.19 (m, 5H), 2.0–1.76 (m, 11H) ppm. 13 C NMR (100 MHz, CDCl3) δ 166.38,165.02, 162.54, 162.8-155.0 (d, CF), 130.06, 128.43, 128.34, 116.01,115.79, 112.46, 71.18, 55.70, 54.13, 47.42, 46.52, 27.94, 25.41, 24.67, 19.58ppm.
[0204] Example 2: (S)-quininecyclo-3-yl(2-(2-(4-fluorophenyl)thiazolyl-4-yl)propyl-2-yl)carbamate (Text) Preparation of the crystalline form of rustatin salt
[0205] Crystalline salts of (S)-quininecyclo-3-yl(2-(2-(4-fluorophenyl)thiazolyl-4-yl)propyl-2-yl)carbamate can be formed from free bases prepared as described in Example 1B.
[0206] For example, a free base (approximately 50 mmol) of (S)-quininecyclo-3-yl(2-(2-(4-fluorophenyl)thiazolyl-4-yl)propyl-2-yl)carbamate is dissolved in IPA (140 ml) at room temperature and filtered. The filtrate is added to a 1 L round-bottom flask equipped with a top stirrer and a nitrogen inlet / outlet. L-malic acid (approximately 50 mmol) is dissolved in IPA (100 + 30 ml) at room temperature and filtered. The filtrate is added to the above 1 L flask. The resulting solution is stirred under nitrogen at room temperature (with or without crystallization) for 4 to 24 hours. During this time, crystals form. The product is collected by filtration and washed with a small amount of IPA (30 ml). The crystalline solid is dried in a vacuum oven at 55°C for 72 hours to produce the desired malate.
[0207] Other salts in crystalline form (e.g., acid addition salts with succinic acid or HCl) can be prepared in a similar manner.
[0208] Example 3: Measurement Protocol
[0209] Reference standards were obtained from commercial sources (GL1, catalog number 1057; C16:0 GM1, Matreya, catalog number 1568; C18:0 GM1, Matreya, catalog number 1569; C24:1 GM1, Matreya, catalog number 1570; GM2, Matreya, catalog number SPL1502-EW and catalog number 1502; 24:1 GM2, Matreya, catalog number CUS9753; GM3, Matreya, catalog number SPL1503-EW). Other chemicals (e.g., solvents) were obtained from commercial suppliers as LC / MS or HPLC grade materials.
[0210] The concentration values obtained using the LC / MS / MS method described herein are affected by the relative abundance of each individual isomer in the reference material, as well as by the instrument and instrument settings. Skilled readers will understand that minor adjustments can be made to the methods described herein to obtain equivalent results using different reference materials and / or instruments.
[0211] Aminohexosidase activity was measured using standard assays (see, for example, Ben-Yoseph et al., Am J HumGenet [American Journal of Human Genetics] (1985) 37(4):733-740).
[0212] Quantification of GL1 in human plasma by LC / MS / MS
[0213] The objective was to validate a method for determining GL1 in human K2EDTA plasma using LC / MS / MS. Defatted human plasma was used as a calibrator and an alternative matrix for assay QC (see, for example, Zheng et al., Mol Genet Metab Rep [Molecular Genetics Metabolism Reports] (2016) 8:77-79). Several assay parameters were also tested on real human plasma samples. Fifty μL of plasma samples were processed using liquid-liquid extraction followed by a SPE procedure. The extracts were dried and reconstituted for LC / MS / MS analysis. Seven GL1 subtypes and the internal standard (N-octadecyl-D35-sphingosine galactoside) were quantified by chromatographic separation via an Xbridge™ HILIC column and ESI-positive MRM scanning on a tandem mass spectrometer.
[0214] The changes in GL-1 subtypes and internal standards monitored on the mass spectrometer are listed in the table below:
[0215]
[0216] LC / MS / MS instruments consisted of a Waters Acquity UPLC and Sciex API 4000 triple quadrupole mass spectrometer or a Shimazu Nexra HPLC and Sciex API 5000 mass spectrometer. LC was equipped with a Waters Xbridge™ HILIC column (3.5 µm, 2.1 × 50 mm) operating at 40°C. For each sample, isocratic elution was performed at 0.5 mL / min for 2 min using a mobile phase consisting of 0.1% formic acid and 2 mM ammonium acetate in a 5:95 water / methanol solution. MS detection was performed using ESI+ ionization. The IonSpray voltage was 5000 V and the temperature was maintained at 500°C. The inlet potential was 9.00 V. Nitrogen was used as the collision, curtain, nebulizer, and auxiliary gas. Spectra were obtained after 2.00 min.
[0217] The total GL1 peak area was obtained by integrating the sum of the intensities of the seven GL1 subtypes using Multiquant™ software. A calibration curve was constructed by linear regression of the peak area ratio of total GL-1 to IS relative to the nominal concentration of the corresponding calibration standard.
[0218] Linear regression and 1 / x were used in the concentration range of 0.1 to 20 µg / mL. 2The method was validated using a weighted factor. Acceptable intra-run and inter-run accuracy and precision were demonstrated. No matrix effect was observed in six individual human plasma batches. GL1 was stable in plasma for up to 26 hours at room temperature, up to 236 days at ≤ -14°C, and 1294 days at ≤ -60°C, and was stable after five freeze / thaw cycles at ≤ -60°C. No interference was observed in human plasma under hemolytic and hyperlipidemic conditions. All assay parameters met the assay acceptance criteria.
[0219] Quantitative analysis of GL1 in human CSF by LC / MS / MS
[0220] The objective was to validate a method for the quantitative detection of GL1 in human CSF using LC / MS / MS. Fifty μL of CSF sample with 0.4% Tween 20 was processed by liquid-liquid extraction followed by LC / MS / MS analysis. Seven GL1 subtypes and an internal standard were separated by chromatographic separation using an Atlantis® HILIC silica column (3 μm, 2.1 x 150 mm) and analyzed by ESI-positive MRM scanning on a tandem mass spectrometer. 13 Quantification was performed using C6-glucosylceramide (isotopically labeled C24:0 GL1, m / z 818.70). Each sample was eluted at a gradient rate of 0.6 mL / min using mobile phase A (96% acetonitrile, 2% methanol, 1% water, 1% acetic acid, 5 mM ammonium acetate) and mobile phase B (98% methanol, 1% water, 1% acetic acid, 5 mM ammonium acetate). MS detection was performed using a Sciex QTRAP-6500 spectrometer with an ion spray voltage of 5500 V and an inlet potential of 10.0 V, maintained at 400°C.
[0221] The total GL1 peak area was obtained by summing the individual integrated peak areas of the seven GL1 subtypes (the same subtypes described above for plasma GL1 determination). In each case, the daughter ion has an m / z of 264.2. Calibration curves were constructed by linear regression of the peak area ratio of total GL1 to IS relative to the nominal concentration of the corresponding calibration standard.
[0222] The method was validated using linear regression and a weighting factor of 1 / x in the concentration range of 2.00 to 200 ng / mL. Acceptable within-run and between-run accuracy and precision were demonstrated. Five-fold dilution with artificial CSF was acceptable. The method showed no matrix effect in six individual human CSF batches containing 0.4% Tween 20. GL1 was stable in human CSF for up to 29 hours at room temperature and after five freeze / thaw cycles, stable for 5.5 months at ≤ -14°C, and stable for up to 39 months at ≤ -60°C. The stability of treated samples was established for 72 hours at 2°C to 8°C and 10 days at ≤ -14°C. The results met the relative matrix effect acceptance criteria. All assay acceptance criteria were met for the assay parameters tested.
[0223] Quantification of total GM1 in human plasma by LC / MS / MS
[0224] The objective was to validate the LC / MS / MS determination of total GM1 in human plasma. Fifty μL of human plasma samples were treated with protein precipitation followed by LC / MS / MS analysis. Six GM1 subtypes and an internal standard (N-hexadecyl-D9-monosialidoganglioside GM1, Materia Medica, catalog number 2057) were detected, and the sum of the six subtypes was quantified using LC / MS / MS.
[0225]
[0226] HPLC was performed using a BEH amide column (130 Å, 1.7 μm, 2.1 x 50 mm) for separation, followed by ESI-positive MRM scanning on a tandem mass spectrometer. Mobile phase A consisted of 85% acetonitrile, 10% methanol, 4% water, and 1% FA. Mobile phase B consisted of 10% methanol, 89% water, and 1% FA. The flow rate was 0.7 mL / min. MS detection was performed using a Sciex QTRAP-6500 spectrometer, which features an ion spray voltage of 5400 V and an inlet potential of 10.0 V, maintained at 350°C.
[0227] The total GM1 peak area was obtained by integrating the sum of the intensities of the six GM1 subtypes using Multiquant™ software. The peak area ratio of total GM1 to IS was then linearly regressed against the nominal concentration of the corresponding calibration standard, and the result was calculated using 1 / x. 2 Weighted averages are used to construct the calibration curve.
[0228] The results showed that the method was accurate and precise from 25.0 to 2000 ng / mL, with an LLOQ of 25.0 ng / mL. A 5-fold dilution with defatted human serum was acceptable. GM1 in human plasma was stable at ambient temperature for up to 6 days, stable for up to 5 freeze / thaw cycles, and stable for up to 12 months at ≤ -14°C and ≤ -60°C. The results met the relative matrix effect acceptance criteria. All assay parameters met the assay acceptance criteria.
[0229] Quantification of GM1 in human CSF by LC / MS / MS
[0230] The objective was to validate the determination of GM1 in human CSF using LC / MS / MS. Fifty μL of human CSF containing 0.3% bovine serum albumin (BSA) was treated with protein precipitation and analyzed by LC / MS / MS. GM1 and IS (N-hexadecyl-D9-monosialidylganglioside GM1, Materia Medica, catalog number 2057) were quantified by chromatographic separation through a Waters BEH amide column (130 Å, 1.7 μm, 2.1 x 50 mm) and ESI-positive MRM scanning on a tandem mass spectrometer, essentially as described above regarding the plasma assay of GM1. GM1 was quantified by summing the intensities of GM1 subtypes Cer36:1 and Cer38:1 (other subtypes were monitored but not quantified). The peak area ratio of GM1 to IS was determined by linear regression relative to the nominal concentrations of the corresponding calibration standards and analyzed using 1 / x. 2 Weighted averages are used to construct the calibration curve.
[0231] The results showed that the method was accurate and precise from 4 to 160 ng / mL, with an LLOQ of 4 ng / mL. A 10-fold dilution with artificial CSF / 0.3% BSA was acceptable. GM1 in human CSF / 0.3% BSA was stable at ambient temperature for up to 30.1 hours, stable for up to 5 freeze / thaw cycles, and stable for up to 7 months at ≤ -14°C and up to 12 months at ≤ -60°C. All assay parameters met the assay acceptance criteria.
[0232] Quantification of total GM2 in human plasma by LC / MS / MS
[0233] The objective was to validate an LC / MS / MS assay for the quantification of total GM2 in human plasma. Two major GM2 subtypes (C18:0 and C24:1) from human plasma were used as GM2 standards in the assay. Ten μL of human plasma was treated with protein precipitation and analyzed by LC / MS / MS. Seven GM2 subtypes and an internal standard (N-hexadecyl-D9-monosialidoganglioside GM2, Materia Medica, catalog number CUS9725) were quantified by LC / MS / MS.
[0234]
[0235] HPLC was performed using an 8.0 min LC gradient program on a Waters BEH amide column (130 Å, 1.7 μm, 2.1 x 50 mm), followed by ESI-positive MRM scanning on a tandem mass spectrometer. Mobile phase A consisted of 85% acetonitrile, 10% methanol, 4% water, and 1% formic acid. Mobile phase B consisted of 10% methanol, 89% water, and 1% FA. The flow rate was 0.4 mL / min. MS detection was performed using a Sciex QTRAP-6500 spectrometer with an ion spray voltage of 5400 V and an inlet potential of 10.0 V, maintained at 350°C.
[0236] The results showed that the method was accurate and precise from 50 to 2000 ng / mL, with an LLOQ of 50 ng / mL. A 5-fold dilution with defatted human serum was acceptable. GM2 in human plasma was stable at ambient temperature for up to 27.9 hours, stable for up to 5 freeze / thaw cycles, and stable for up to 6 months at ≤ -14°C and 24 months at ≤ -60°C. All assay parameters met the assay acceptance criteria.
[0237] Quantitative analysis of GM2 in human CSF by LC / MS / MS
[0238] The objective was to validate the LC / MS / MS assay for quantifying GM2 (C18:0) in human CSF. Fifty μL of CSF was treated with protein precipitation followed by LC / MS / MS analysis. GM2 and the internal standard (N-hexadecyl-D9-monosialidylganglioside GM2, Materia Medica, catalog number CUS9725, primarily C18:0) were quantified by chromatographic separation via a BEH amide column and ESI-positive MRM scan on a tandem mass spectrometer, essentially as described above for the plasma assay of GM2. The temperature during the MS / MS stage was maintained at 450°C, under which the IS had a Q3 mass of 204.2 Da. C24:1 GM2 was not quantified in this method. Linear regression of the peak area ratio of GM2 to IS relative to the nominal concentration of the corresponding calibration standard was performed using 1 / x. 2 Weighted averages are used to construct the calibration curve.
[0239] This method is applicable to the determination of GM2 (C18:0) in human CSF with 0.3% BSA in the range of 2.50 ng / mL (LLOQ) to 250 ng / mL. Dilution with artificial CSF / 0.3% BSA up to 5-fold is acceptable. GM2 in human CSF is stable at ambient temperature for up to 24 hours, stable for up to 5 freeze / thaw cycles, stable at ≤ -14°C for up to 3 months, and stable at ≤ -60°C for up to 42 months. All assay parameters meet the assay acceptance criteria.
[0240] Quantification of total GM3 in human plasma by LC / MS / MS
[0241] The objective was to validate an LC / MS / MS assay for quantifying total GM3 in human plasma. Twenty μL of human plasma samples were treated with protein precipitation and analyzed by LC / MS / MS (see also, for example, Peterschmitt et al., Clin PharmDrug Dev [Clinical Pharmacy Drug Development] (2021) 10(1):86-98, Supplementary Material). Seven GM3 subtypes and an internal standard (gangliotrisaccharide ceramide GA2, Materia Medica, catalog number 1512) were quantified.
[0242]
[0243] HPLC was performed using an XBridge™ BEC HILIC column (130 Å, 3.5 μm, 2.1 x 50 mm; Waters) with LC gradient program, followed by ESI-positive MRM scanning on a tandem mass spectrometer. Mobile phase A consisted of 97% acetonitrile, 2% methanol, 1% acetic acid, and 5 mM ammonium acetate. Mobile phase B consisted of 99% methanol, 1% acetic acid, and 5 mM ammonium acetate. The flow rate was 1.0 mL / min. MS detection was performed using a Sciex API4000 spectrometer with an ion spray voltage of 5000 V and an inlet potential of 10.0 V, maintained at 400°C.
[0244] The total GM3 peak area was obtained by integrating the sum of the intensities of the seven GM3 subtypes using Multiquant™ software. The peak area ratio of total GM3 to IS was then linearly regressed against the nominal concentration of the corresponding calibration standards, and the result was calculated using 1 / x. 2 Weighted averages are used to construct the calibration curve.
[0245] The results showed that the method was accurate and precise from 4.0 to 80 µg / mL, with an LLOQ of 4.0 µg / mL. Hemoglobin, bilirubin, or lipids did not interfere. GM3 in human plasma was stable for up to 7 days at ambient temperature, stable for up to 5 freeze / thaw cycles, stable for up to 5 days at 2°C–8°C, stable for up to 1 month at ≤ -14°C, and stable for up to 24 months at ≤ -60°C. All assay parameters met the assay acceptance criteria.
[0246] Quantitative analysis of GM3 in human CSF by LC / MS / MS
[0247] The objective was to validate the LC / MS / MS determination of total GM3 in human CSF. Forty μL of CSF with 0.3% BSA was treated with protein precipitation and analyzed by LC / MS / MS. Seven GM3 subtypes (the same subtypes assessed in GM3 plasma assays) and the internal standard (C16:0 GM3-[palmitoyl-D31], Q1 mass = 1184.9 Da, Q3 mass = 265.4 Da) were quantified by chromatographic separation through a BEHamide column (130 Å, 1.7 μm, 2.1 x 50 mm; Waters) and ESI-positive MRM scans from a tandem mass spectrometer. Mobile phase A consisted of 90% acetonitrile, 5% methanol, 4% water, and 1% FA. Mobile phase B consisted of 50% methanol, 49% water, and 1% FA. The flow rate was 0.6 mL / min. MS detection was performed using a Sciex Qtrap 6500 spectrometer, which has an ion spray voltage of 5500 V and an inlet potential of 10.0 V, with the temperature maintained at 350°C.
[0248] The total GM3 peak area was obtained by integrating the sum of the intensities of the seven GM3 subtypes using Multiquant™ software. The peak area ratio of total GM3 to IS was then linearly regressed against the nominal concentration of the corresponding calibration standards, and the result was calculated using 1 / x. 2 Weighted averages are used to construct the calibration curve.
[0249] The results showed that the method was accurate and precise from 5 to 200 ng / mL, with an LLOQ of 5 ng / mL. A 5-fold dilution with artificial CSF / 0.3% BSA was acceptable. The method demonstrated acceptable extraction recoveries and relative matrix effects. GM3 in human CSF / 0.3% BSA was stable at ambient temperature for up to 26.1 hours, stable for up to 5 freeze / thaw cycles, and stable for up to 6 months at ≤ -14°C and 24 months at ≤ -60°C. All assay parameters met the assay acceptance criteria.
[0250] Example 4: Assessment of biomarker levels in healthy individuals
[0251] The assays described in Application Example 3 were used to test biomarker levels in plasma and CSF samples collected from healthy individuals (CSF samples from PrecisionMed, Carlsbad, California; and plasma samples from BioIVT, Westbury, New York). The table below indicates the range of values measured:
[0252] Table 1: Normal ranges of biomarkers in plasma and CSF samples
[0253]
[0254] 1 Both plasma GM3 and GL1 were measured with n = 100 samples, and the data were reported from min to max (i.e., not the 95th percentile).
[0255] Example 5: Evaluation of biological activity in patients with GM2 ganglioside storage disorder and other ganglioside storage disorders Marker level
[0256] As part of a study on the effects of venulose on patients with GM2 ganglioside storage disease and other ganglioside storage diseases, plasma and CSF levels of multiple biomarkers were measured over a 104-week period. Samples were analyzed based on the above measurements.
[0257] Patient demographics and research details
[0258] Patients were recruited into two groups: a primary group of adults with late-onset GM2 ganglioside storage diseases (Sanderhoff's disease and Ty-Sachs disease) and a secondary group including juvenile GM2 ganglioside storage diseases, GM1 ganglioside storage diseases, and type I sialic acid storage diseases. At the start of the study, all patients were at least 2 years old and weighed ≥10 kg. Demographic and baseline characteristics of the two groups are shown in Table 2 below:
[0259] Table 2: Demographic and Baseline Characteristics
[0260]
[0261] Unless otherwise stated, data are presented as mean ± standard deviation or median [interquartile range].
[0262] The study aims to cover four main periods:
[0263] - Phase 1 (Day -60 to Day -1): Screening and assessment.
[0264] - Phase 2 (Week 0 to Week 104): Primary treatment and analysis period. Participants in the primary cohort were randomly assigned in a double-blind design to receive venlulstat or placebo once daily. Participants in the secondary cohort received venlulstat for 104 weeks in an open-label design.
[0265] - Phase 3 (Week 104 to Week 208): Open-label period. Participants in both the primary and secondary populations automatically enter the OLE period after Phase 2.
[0266] - Period 4 (weeks 208 to 214). A 6-week safety observation period following treatment.
[0267] Screening assessment includes medical history and (where appropriate) confirmation of diagnosis through genotyping, for example, confirming the diagnosis of Sandhof disease and Ty-Sachs disease in the main population by genotyping HEXA / HEXB.
[0268] Venllustat is administered once daily at a dose of 15 mg to adult patients (18 years of age and older). Patients <18 years of age are administered once daily at doses of 4 mg, 6 mg, 12 mg, or 15 mg (based on free base) according to their weight.
[0269]
[0270] The plan is to collect biological samples from participants during the following visits:
[0271]
[0272] CSF is collected via lumbar puncture according to standard clinical practice. Approximately 7–8 mL is collected, discarding the first 1–2 mL. Plasma is also collected according to standard clinical practice.
[0273] Biomarker Analysis and Results - Major Population
[0274] Table 3 below shows the changes in CSF biomarker levels (median values, with lower and upper quartile ranges and number of patients shown in parentheses) in patients with Ty-Sachs disease and Sandhoff's disease. Results are shown separately in the placebo group (n = 13 at baseline for Ty-Sachs disease and n = 5 at baseline for Sandhoff's disease) and the venlucalusol treatment group (n = 29 at baseline for Ty-Sachs disease and n = 10 at baseline for Sandhoff's disease):
[0275] Table 3: CSF levels of biomarkers in major populations
[0276]
[0277] Table 4 below shows the changes in plasma biomarker levels (median values, with lower and upper quartile ranges and number of patients shown in parentheses) in patients with Ty-Sachs disease and Sandhoff's disease:
[0278] Table 4: Plasma levels of biomarkers in major populations
[0279]
[0280] "-" indicates that the biomarker was not measured.
[0281] The degree of reduction in CSF GM2 in the entire major population is as follows Figure 2 The change is shown as a percentage relative to baseline. This illustrates a significant difference between patients in the placebo and venlustat treatment groups (estimated difference of -36.2%, 90% confidence interval [-44.8% to -27.7%], one-sided p < 0.0001).
[0282] The percentage change in biomarker levels in the Tay-Sachs and Sandhoff disease groups is shown in Figures 3 to 5 The percentage changes in CSF levels for GM2, GM3, and GL1 at week 104 are shown in the figures below. Figure 3 A, Figure 4 A and Figure 5 In group A, the percentage changes in plasma GM2, GM3, and GL1 levels at weeks 12–104 in the Tay-Sachs and Sandhoff disease groups are shown in Figures A. Figure 3 B Figure 4 B and Figure 5 B in.
[0283] Figure 6 The correlation between baseline aminohexosidase levels and the percentage change in CSFGM2 was shown in patients treated with venlustat in the primary population.
[0284] Biomarker Analysis and Results - Secondary Population
[0285] Table 5 below shows the changes in CSF biomarker levels in patients with GM1 ganglioside storage disease (n = 7 at baseline), juvenile GM2 ganglioside storage disease (n = 7 at baseline), and sialic acid storage disease (n = 1). Only the median values for patients with GM1 and juvenile GM2 ganglioside storage disease are shown, with the lower and upper quartile ranges (and the number of patients) indicated in parentheses.
[0286] Table 5: CSF levels of biomarkers in secondary populations
[0287]
[0288] "-" indicates that the biomarker was not measured.
[0289] Table 6 below shows the changes in plasma biomarker levels in patients with GM1 ganglioside storage disease, juvenile GM2 ganglioside storage disease, and sialic acid storage disease. Only the median values for patients with GM1 and juvenile GM2 ganglioside storage disease are shown, with the lower and upper quartile ranges (and the number of patients) indicated in parentheses.
[0290] Table 6: Plasma levels of biomarkers in secondary populations
[0291]
[0292] "-" indicates that the biomarker was not measured.
[0293] The percentage change in biomarker levels in the secondary population is shown in Figures 7 to 9 The percentage changes in CSF levels of GM1, GM2, and GL1 at baseline and at week 104 are shown in the figures. Figure 7 A, Figure 8 A and Figure 9 In A, the percentage changes in plasma levels of GM1, GM2, and GL1 at baseline and during weeks 12–104 are shown in Figures 1–2. Figure 7 B Figure 8 B and Figure 9 B in.
[0294] Safety and adverse events
[0295] Consistent with earlier studies, venelulstat was generally well tolerated in both the primary and secondary populations. Eight participants in the primary population discontinued the study (two in the placebo group and six in the venelulstat treatment group). Adverse events were reported in both the placebo and venelulstat treatment groups at similar frequencies, including injury, infection, gastrointestinal events, neurological events, musculoskeletal events, respiratory events, psychiatric events, and skin events.
[0296] in conclusion
[0297] Subjects treated with venlucalusstat showed significantly reduced CSF and plasma disease biomarkers. Compared with placebo, significantly reduced CSF GM2 levels were observed in adult patients with GM2 ganglioside storage disease, significantly reduced GM1 levels were observed in patients with GM1 ganglioside storage disease, significantly reduced GM2 levels were observed in patients with juvenile GM2 ganglioside storage disease, and significantly reduced GM3 levels were observed in patients with sialic acid storage disease.
[0298] Example 6: Assessing disease-related protein levels in CSF of patients with GM1 and GM2 ganglioside storage disorders
[0299] Following the study described in Example 5, CD63 and NFL levels were tested in CSF samples from the primary and secondary populations (GM1 ganglioside storage disease and juvenile GM2 ganglioside storage disease only).
[0300] Sample processing and analysis protocols
[0301] Samples were used during the study described in Example 5. Samples were stored at -70°C (or lower) for varying lengths of time, with baseline samples collected at least 2 years prior to analysis and week 104 samples collected less than 1 year prior to analysis. Samples were thawed prior to testing (some samples were thawed more than once).
[0302] According to the manufacturer's instructions, CD63 concentration was measured using the Olink® spectrophotometry kit (Olink Proteomics AB, Uppsala, Sweden), as detailed below. NFL concentration was measured using the Simoa® NF-light™ V2 Advantage kit (Quanterix) on the HD-X™ Automated Immunoassay Analyzer, according to the manufacturer's instructions. More generally, methods that can be used to measure CD63 or NFL concentrations in CSF include immunoassays (e.g., ELISA, microfluidic ELISA, or bead-based high-sensitivity ELISA; capillary blot assays; nanoneedle bioarrays (e.g., from Nanomasaic®), proximity assays (e.g., NULISA®; or PEA), other affinity-based assays (e.g., nucleic acid-binding aptamers from Somalogic®) or mass spectrometry.
[0303] For the CD63 Olink assay, 10 µL of CSF sample and Olink control were placed in a 384-well sample source plate and then diluted in 384-well sample dilution plates at 1:10, 1:100, 1:1000, and 1:100,000 using a Mosquito and a Dragonfly liquid processor (both from SPT Labtech). For the immunoreaction, these diluted samples were mixed with Olink® probes (DNA oligonucleotide-conjugated antibodies) in 384-well incubation plates using a Mosquito processor and incubated at 4°C for 16–24 hours. The next day, PCR reagents were added to the immunoreaction mixture using a Dragonfly processor, and PCR reactions were performed using a ProFlex PCR system (Applied Biosciences). PCR products were collected to create libraries using an epMotion 5075 liquid processor (Eppendorf), which were then purified using magnetic beads and QC performed using a Bioanalyzer 2100 (Agilent). The libraries were then analyzed by next-generation sequencing using a NovaSeq 6000 (Illumina). Any samples failing quality control were excluded from further analysis. Final assay readouts are presented as normalized protein expression (NPX) values, which are arbitrary units on a log2 scale, where higher values correspond to higher protein expression. All assay validation data (e.g., limits of detection, intra- and inter-assay precision data, etc.), experimental protocols, and data processing are available on the manufacturer's website (www.olink.com).
[0304] For NFL concentration measurements, following the manufacturer's protocol, the CSF sample was diluted 100-fold using sample dilution buffer (Quanterix) and then analyzed using Simoa assay.
[0305] Results and discussion
[0306] Baseline CD63 levels in CSF samples from the primary and secondary populations are shown in... Figure 10 (CD63 levels are shown on a linear scale and in 2) NPX(BL) Calculate, i.e., 2 raised to the power of the baseline NPX level. Figure 11 The percentage change in CD63 levels at week 104 in the CSF (compared to baseline) is shown. The percentage change is calculated according to the following equation, where NPX(104) represents the NPX value at week 104, and NPX(BL) represents the NPX value at baseline:
[0307]
[0308] Figure 10 and Figure 11 The results shown indicate that administration of venulister to patients with GM2 ganglioside storage disease (childhood and adulthood) can lead to a decrease in CD63 levels in the CSF.
[0309] Baseline NFL levels in CSF samples from the primary and secondary populations are shown in Figure 12 (in pg / mL) Figure 13 The percentage change in CD63 levels in the CSF at week 104 (compared to baseline) is shown. These results indicate that administration of venlulositol in patients with juvenile GM2 ganglioside storage disease can lead to a decrease in NFL levels in the CSF.
[0310]
[0311] It should be understood that although this disclosure has been described in conjunction with the foregoing embodiments, the foregoing description and examples are intended to illustrate and not limit the scope of this disclosure. Other aspects, advantages, and modifications within the scope of this disclosure will be apparent to those skilled in the art to which this disclosure pertains.
[0312] Furthermore, when a feature or aspect is described in terms of a Markush group, those skilled in the art will recognize that such a feature or aspect is also described in terms of a single member or a subgroup of any member of that Markush group.
[0313] All publications, patent applications, patents, and other references mentioned herein are expressly incorporated in their entirety by reference as if they were individually incorporated by reference. In the event of any conflict, this specification, including its definitions, shall prevail.
Claims
1. A method for reducing the level of a biomarker in the biological fluid of a subject in need of having a ganglioside storage disorder, the method comprising administering to the subject an effective amount of venulostatine or a pharmaceutically acceptable salt thereof, wherein the biomarker is selected from the group consisting of GM1, GM2, GM3, GL1 and combinations thereof.
2. A method of administering venollustat or a pharmaceutically acceptable salt thereof to a subject in need suffering from ganglioside storage disorder, wherein the venollustat or a pharmaceutically acceptable salt thereof is administered in an effective amount to reduce the level of biomarkers in the subject's biological fluid.
3. The method of claim 1 or claim 2, wherein the biological fluid is selected from the group consisting of plasma and CSF.
4. The method of any one of claims 1 to 3, wherein the biomarker is selected from: (a) GM1, optionally in combination with GM3 and / or GL1; (b) GM2, optionally in combination with GM3 and / or GL1; and (c) GM3, optionally in combination with GM2 and / or GL1.
5. The method of any one of claims 1 to 4, wherein the administration of the venulostatine or a pharmaceutically acceptable salt thereof reduces the level of the biomarker by at least about 30%, for example at least about 40%, 50%, 60%, 70% or 80%.
6. The method of any one of claims 1 to 5, wherein the venulstat or a pharmaceutically acceptable salt thereof is administered orally, for example, in the form of tablets or capsules.
7. The method of any one of claims 1 to 6, wherein the venulstat or a pharmaceutically acceptable salt thereof is administered once daily.
8. The method of any one of claims 1 to 7, wherein the subject is 18 years of age or older and is administered venlucalstat or a pharmaceutically acceptable salt thereof at a dose of about 15 mg / day (calculated as free base); or wherein the subject is under 18 years of age and is administered venlucalstat or a pharmaceutically acceptable salt thereof at a dose of (calculated as free base): (a) For subjects weighing ≥ 50 kg, approximately 15 mg / day; (b) For subjects weighing 30 kg to < 50 kg, approximately 12 mg / day; (c) For subjects weighing 15 kg to < 30 kg, approximately 6 mg / day; or (d) For subjects weighing 10 kg to < 15 kg, approximately 4 mg / day.
9. The method of any one of claims 1 to 8, wherein the venollustat is in the form of a free venollustat base or a pharmaceutically acceptable salt of venollustat, optionally in the form of venollustat L-malate.
10. The method of any one of claims 1 to 9, wherein the ganglioside storage disorder is selected from GM2 ganglioside storage disorder (e.g., Sandhoff's disease or Tai-Sachs disease) and GM1 ganglioside storage disorder.
11. A method for reducing the level of a biomarker in a biological fluid of a subject in need of GM2 ganglioside storage disorder, the method comprising administering to the subject an effective amount of venulilstat or a pharmaceutically acceptable salt thereof, wherein the biomarker is GM2, optionally in combination with GM3 and / or GL1.
12. The method of claim 11, wherein: (a) The GM2 ganglioside storage disorder is Ty Sachs disease, and the administration of venulilstat or a pharmaceutically acceptable salt thereof reduces the GM2 level in the CSF by at least about 30%; or (b) The GM2 ganglioside storage disorder is Sandhoff's disease, and the administration of venulilstat or its pharmaceutically acceptable salt reduces the GM2 level in the CSF by at least about 40%.
13. The method of claim 11, wherein the GM2 ganglioside storage disease is juvenile GM2 ganglioside storage disease, and the administration of venollustat or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) the GM2 level in the CSF by at least about 30%.
14. The method of any one of claims 11 to 13, wherein administration of the venulister or a pharmaceutically acceptable salt thereof reduces the plasma GM2 level to a level between about 200 ng / mL and about 750 ng / mL.
15. A method for reducing the level of a biomarker in a biological fluid of a subject in need of GM1 ganglioside storage disorder, the method comprising administering to the subject an effective amount of venulilstat or a pharmaceutically acceptable salt thereof, wherein the biomarker is GM1, optionally in combination with GM3 and / or GL1.
16. The method of claim 15, wherein administration of the venulister or a pharmaceutically acceptable salt thereof reduces the GM1 level in the CSF to a level between about 25 ng / mL and 65 ng / mL, and / or reduces the GM1 level in the plasma to a level between about 40 ng / mL and about 115 ng / mL.
17. The method according to any one of claims 1 to 16, wherein: (i) This method also reduced the level of CD63 in the subject's CSF; (ii) Administration of an effective amount of venulilstat or a pharmaceutically acceptable salt thereof also reduced the CD63 level in the subject's CSF; or (iii) Administration of this effective amount of venulilstat or a pharmaceutically acceptable salt thereof also reduced the CD63 level in the subject's CSF. The subject suffered from ganglioside storage disorder, specifically GM2 ganglioside storage disorder.
18. The method of claim 17, wherein: (a) The GM2 ganglioside storage disorder is adult-onset Ty Sachs disease or adult-onset Sandhoff disease, and administration of venulister or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) CD63 levels in the CSF by at least about 30%; or (b) The GM2 ganglioside storage disease is juvenile GM2 ganglioside storage disease, and the administration of venlustat or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) the CD63 level in the CSF by at least about 35%.
19. The method according to any one of claims 1 to 18, wherein: (i) This method also reduced the level of NFL in the subject's CSF; (ii) Administration of an effective amount of venulilstat or a pharmaceutically acceptable salt thereof also reduced the NFL level in the subject's CSF; or (iii) Administration of this effective amount of venulilstat or its pharmaceutically acceptable salt also reduced the NFL level in the subject's CSF. The subject suffered from ganglioside storage disorder, specifically juvenile GM2 ganglioside storage disorder.
20. The method of claim 19, wherein the administration of the venulosamine or a pharmaceutically acceptable salt thereof reduces (or effectively reduces) the NFL level in the CSF by at least about 50%.
21. A venulstat or a pharmaceutically acceptable salt thereof for use in the method as described in any one of claims 1 to 20.
22. Use of venulstat or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical agent for use in any one of claims 1 to 20.
Citation Information
Patent Citations
Glucosylceramide synthase inhibitors
WO2012129084A2
SALT FORMS OF (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate
WO2014152215A1
Pharmaceutical compositions comprising venglustat
WO2022018695A1
Biomarkers of lysosomal storage disease
WO2024018382A1
